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Abstract 
 
The use of enzymes for protein modification chemistry has gained traction in 
recent years due to the remarkable site-selectivity that enzymes afford. Among 
enzymes reported for this purpose, sortase A from Staphylococcus aureus (SrtAStaph) 
has garnered significant attention because of its selectivity, and its ability to install a 
wide range of non-natural modifications. In addition to SrtAStaph, it is now appreciated 
that sortase homologs exist in many bacterial strains, each with the potential to 
serve as a new catalyst for protein engineering. However, the majority of these 
enzymes has not been studied biochemically, and in order to utilize these enzymes 
for protein modification it is critical that the activity and specificity of each enzyme be 
verified experimentally. This includes determination of optimal substrate sequences 
and amine nucleophile preferences. Here we present progress toward characterizing 
the in vitro substrate specificity of ten sortase homologs using libraries of synthetic 
peptide substrates.  
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1. Introduction 
1.1 Chemoenzymatic Protein Conjugation Chemistry 
Site-specific protein modification represents a very active area of modern 
biotechnology. While challenging, methods for constructing proteins possessing non-
natural functional groups provide access to derivatives with unique properties for a 
range of medical, basic research, and industrial applications.1-3 Examples include 
the introduction of fluorophores2, antibody-drug conjugates3, or another small 
molecules onto the proteins for examining protein structure4, folding4, dynamics4, 
and protein-protein interactions4. The inherent difficulty in preparing modified 
proteins lies in the large number of reactive functional groups typically encountered 
in polypeptides. These functional groups include the primary amine side chain of 
lysine residues, the nucleophilic thiol of cysteines, the carboxylic acid side chains of 
aspartic and glutamic acids, as well as others. Early methods of protein 
functionalization often exploited the reactivity of lysine or cysteine residues through 
the reaction of proteins with an excess of reagents such as N-hydroxysuccinimidyl 
esters1,5,6, iodoacetamides1,7, or maleimides1,7-9. While these chemical reactions are 
able to distinguish between different amino acid side chains, they are typically not 
able to distinguish between multiple copies of the same amino acid side chain, and 
therefore they are not site-specific. Site-specific modification is highly desirable 
because it allows control of the placement of desired modifications onto a target 
protein at a precise location. 
 Recently, chemoenzymatic strategies have emerged as powerful methods for 
performing site-specific protein modifications.1,7,10 These methods are distinct from 
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standard chemical approaches in that they exploit an enzyme’s ability to recognize 
groups of amino acids, rather than single amino acids. The overall strategy is 
depicted in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemoenzymatic site-specific protein modification. 
 
An enzyme substrate motif is introduced into a target protein often using site-
directed mutagenesis. The target protein is then paired with a specific enzyme that is 
able to target the substrate motif and install a useful non-natural modification. 
Common enzymes used for chemoenzymatic protein modification include biotin 
ligase11-13, transglutaminase14-17, lipoic acid ligase18-20 and formylglycine generating 
enzyme21-24. Biotin and lipoic acid ligases catalyze the attachment of biotin and lipoic 
acid mimics onto lysine residues in the enzyme substrate motif.11-13,18-20 
Formylglycine generating enzymes are responsible for a post-translational 
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modification of type I sulfatases.21-24 This alteration involves the change of cysteine 
within a CXPXR substrate motif to an aldehyde bearing residue, and has been 
replicated on recombinant protein targets. In addition to the site-specificity of 
chemoenzymatic strategies, these methods are also attractive because they operate 
under mild conditions that preserve the function of the protein target.  
 
1.2 Sortase Function In Vivo 
Among enzymes reported for chemoenzymatic protein modification, the bacterial 
sortases have emerged as exceptionally powerful tools. Sortase enzymes are 
membrane-bound transpeptidases found in gram-positive bacteria. They are known 
to catalyze the attachment of proteins to the bacterial cell wall (Figure 2).25,26 The 
first member of this enzyme family that was discovered was sortase A from 
Staphylococcus aureus (SrtAStaph).27 SrtAstaph recognizes a substrate motif known as 
the “sorting signal”, which contains a LPXTG (X may be any amino acid) sequence 
near the C-terminus of target proteins.25,28 SrtAStaph possesses an active-site 
cysteine present at residue 184, and the thiol side chain cleaves the amide bond 
between the threonine and glycine residues of the LPXTG motif. This generates a 
thioester linked acyl-enzyme intermediate that is then intercepted by an amine 
nucleophile present in the interpeptide bridge portion of the cell wall component lipid 
II.29 Overall, this transpeptidation reaction results in covalent anchoring of the 
LPXTG-containing protein to the bacterial cell wall.  
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Figure 2. In vivo reaction of sortase A from S. aureus 
 
Lipid II is a critical peptidoglycan precursor, which contains a long 
hydrophobic tail, two carbohydrate residues (N-Acetylmuramic acid and N-
acetylglucosamine), and a peptide portion that varies between different bacterial 
species (Figure 3).30 In the case of S. aureus, the key structural element that 
participates in the sortase A catalyzed transpeptidation reaction is the pentaglycine 
sequence located in the interpeptide bridge.31 The amino N-terminus of this peptide 
is responsible for breaking down the sortase acyl-enzyme intermediate and 
completing the catalytic cycle.29,31 This results in formation of a new peptide bond 
between lipid II and the LPXTG containing protein.  
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Figure 3. The structure of the Lipid II molecule found in Staphylococcus aureus.  
 
Since the discovery of SrtAStaph, it has become evident that homologs of this 
enzyme exist across a range of bacterial species.32 Sortases are currently grouped 
into six subclasses (A-F) based on sequence similarity. Sortase A has a 
“housekeeping role” in modifying the bacterial surface.25 Nearly all Firmicutes 
contain sortase A enzymes which are believed to attach proteins to the cell wall by 
ligation to lipid II.25,33,34 Sortase B is involved in nutrient intake, for example through 
the anchoring of heme proteins to the cell wall.35 Sortase C is involved in the 
construction of bacterial pilli, which promotes microbial adhesion and biofilm 
formation.36,37 Comparatively less is known regarding sortases D,E, and F.25 
In all cases, sortases are believed to catalyze a variation of the basic 
transpeptidation reaction shown in Figure 2. However, depending on the particular 
organism, this may involve variations of the LPXTG motif, as well as differences in 
the amine nucleophile of lipid II. For example, sortase B from S. aureus has been 
7 
Nucleophilic  
Amine 
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shown to process NPQTN motifs, while sortase B from C. difficile has been shown to 
accept SPKTG substrates.38,39 Other variations of the five amino acid sorting motif 
have been predicted, though in most cases these have not been experimentally 
verified.40 With respect to amine nucleophiles, lipid II variants in different bacterial 
species suggest that certain sortase homologs may accept N-terminal alanines, N-
terminal serines, the ε-amine of the lysine chain, or meso-diaminopimelic acid as 
alternatives to N-terminal glycines.29,34,41 An additional important variation in 
nucleophile structure is observed in the sortase C subclass. Rather than utilizing 
lipid II, these enzymes accept the ε-amine of the lysine chain present in protein 
subunits used to generate the bacterial pilus.42 
Sortases have been shown to play a profound role in bacterial virulence. The 
proteins attached to the cell wall possess a range of functions including promoting 
bacterial adhesion, nutrient acquisition, host cell invasion, and immune 
evasion.25,26,39,43 In the case of S. aureus, specific examples of proteins that are 
anchored via a sortase-catalyzed process include surface protein A, which is 
involved in binding the Fc region of host antibodies, as well as fibronectin binding 
proteins, which are involved in bacterial adhesion and biofilm formation.44,45 Given 
the role that sortases play in bacterial virulence, they are currently regarded as 
promising targets for therapeutic intervention. Inactivation of sortase genes in 
bacteria such as S. aureus and L monocytogenes has been shown to reduce 
disease progression in animal infection models.46-48 In addition, small molecule 
inhibitors have shown promising therapeutic outcomes in mouse infection 
models.49,50 
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1.3 Sortase-Based Protein Conjugation Protein Chemistry  
 
Shortly after the discovery of SrtAStaph in S. aureus, it was demonstrated that 
the transpeptidation reaction catalyzed by this enzyme could be replicated in vitro. 51 
In 2004, it was reported that this chemistry could be exploited as means for site-
specifically modifying protein targets.51 In this strategy, a protein target is engineered 
to display a LPXTG sequence near its C-terminus. This is paired with a soluble, 
recombinant variant of SrtAStaph and a synthetic amine nucleophile containing at 
least one N-terminal glycine residue appended to a useful non-natural protein 
modification (Figure 4).52-54 In the presence of Ca2+, SrtAStaph catalyzes the site-
specific attachment of the synthetic nucleophile to the protein C-terminus. In addition 
to C-terminal modification, the strategy can be adapted to N-terminal modification by 
simply switching the arrangement of the LPXTG motif and the glycine nucleophile 
(Figure 4).52,55 
 
 
 
 
 
 
 
 
 
 
Figure 4. Site-specific protein modification using SrtAStaph-mediated transpeptidation. 
 
In this system, the protein target serves as the glycine nucleophile, and the non-
natural modification is appended to a synthetic LPXTG peptide substrate. Over the 
last eleven years, sortase-based strategies for protein modification have found use 
in a wide range of different applications. These include the construction of 
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fluorescently-labeled proteins, artificial lipoproteins, protein-polymer conjugates, 
unique protein-protein fusions, and antibody derivatives. Sortases have also seen in 
use in attaching proteins to solid supports and the surface of live cells.56-60 
 As a specific example, Donnely et al. demonstrated the site-specific 
bioconjugation of a radioactive metal complex to a single-chain antibody using 
SrtAStaph. They reported the synthesis and isolation of bifunctional chelators and 
demonstrated their ability for high-yielding, site-specific and reproducible 
modification of a scFv antibody against platelet integrin GPIIb/IIIa in its active ligand-
bound form (Figure 5).61 These SrtAStaph generated scFV conjugates were then 
shown to provide excellent imaging agents for visualizing activated platelets in a 
mouse model for carotid thrombosis. 
 
 
 
 
 
 
 
 
 
Figure 5. SrtAStaph-mediated conjugation of 64Cu chelator to anti-LIBS scFV. 
 
Sortase enzymes have also been utilized to remodel the surface of live cells. 
In 2014, Shi et al. demonstrated that red blood cells could be engineered to display 
LPXTG-containing proteins or proteins with nucleophilic glycines on their surface 
+ -LPETGG-FLAG 
ScFV-Anti 
LIBS 
sortase A 
64Cu 
64Cu 
ScFV-Anti 
LIBS 
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(Figure 6).62 These proteins could then be targeted using a SrtAStaph-catalyzed 
transpeptidation reaction to install a range of modifications including biotin or 
antibody fragments. These modified cells were then found to exhibit circulation 
behavior that mimicked wild type red blood cells, suggesting that this approach could 
provide a new strategy for systemic delivery of a range of non-natural entities.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic for cell surface engineering of red blood cells. 
 
As a final example, Jiang et al. reported a straightforward and robust site-
specific double modification of recombinant thrombomodulin (TM456) by PEGylation 
through strain-promoted alkyne–azide cycloaddition (SPAAC) and tagging with a 
variety of functionalities such as fluorescent dyes or affinity handles through sortase 
mediated ligation (Figure 7).10 Modification with a polymer such as polyethylene 
glycol (PEG) was performed to improve the pharmacokinetics of recombinant 
TM456.
 In addition, a fluorescent probe was added to assist with purification and 
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recognition of recombinant TM456 in both in vitro and in vivo experiments. Ultimately 
they were able to successfully modify TM456 with dual modifications without affecting 
its anticoagulatory activity. Sortase-mediated ligations were achieved via the C-
termini of TM456 using an installed LPETG sorting motif. Strain-promoted alkyne-
azide cycloaddition was completed with using cyclooctynes appended to PEG or 
BODIPY fluorophores.  
 
 
 
 
 
 
 
 
 
Figure 7. Site-specific dual-modification of recombinant TM456 using sortase-mediated ligation and 
SPAAC strategies.  
Overall, these examples demonstrate the increasing variety of uses of 
SrtAStaph, and show that sortase-mediated protein engineering provides an efficient 
and reliable method for site-specific modification of proteins and peptides. However, 
while the range of applications of sortase-based methods has continued to increase, 
the chemistry itself has seen relatively few improvements despite some notable 
limitations. These include the fact that SrtAStaph is typically limited to LPXTG 
substrates, ligation efficiency is limited by reaction reversibility, the rates of in vitro 
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transpeptidation are poor, and the method is best suited to ligations targeting the N- 
and C-termini of protein and peptide substrates. Important progress has been made 
in addressing some of these issues. In 2014, it was reported that SrtAStaph can be 
used to install modifications at internal lysine residues, providing a way for placing 
modifications at sites other than the protein termini.63 In addition, a handful of 
strategies have emerged for blocking reaction reversibility as a means for improving 
overall reaction efficiency.64-66 With regard to reaction rates and substrate ranges, 
directed evolution has furnished sortases with improved reaction kinetics and slightly 
expanded substrate scope.67-69 While promising, these evolved sortases still only 
process a limited number of five amino acid substrate sequences. Thus there are 
many important opportunities to further expand the substrate scope of sortase-based 
protein engineering methods. 
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1.4 Expanding Sortase Substrate Scope 
 Two strategies have been employed to date to expand the substrate scope of 
sortase-mediated transpeptidation reactions. The first involves directed evolution 
starting with the wild type SrtAStaph enzyme. In 2011, Piotukh et al. employed a 
phage display strategy to identify SrtAStaph mutants with relaxed substrate 
specificity.67 The authors created a library of mutants focusing on the β6-β7 loop of 
SrtAStaph, which has been shown to be critical for substrate recognition. From this 
library, two mutants were identified that demonstrated the ability to target alternate 
residues in the leucine position of the LPXTG motif (Figure 8).67 Specifically, 
mutants tolerated A, D, S, F, and M in the leucine position of the original LPXTG 
motif, however, in all cases reaction conversion was relatively poor (≤ ~20%). 
Nonetheless, the authors were able to demonstrate the use a mutant sortase to 
generate a semisynthetic derivative of histone H3 through a traceless ligation at an 
APATGG site which naturally occurs in near the C-terminus of this protein. 
 
 
 
 
 
 
 
 
Figure 8. Comparison of native SrtAStaph substrate specificity to evolved sortase variants.67,68 
 
-LXETG-  
-LPEXG-  
-LPXTG-  
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 As an additional example of using directed evolution to expand sortase 
substrate scope, Dorr et al. reported a yeast display strategy for the evolution of two 
orthogonal sortase A variants that recognize the unique substrates LAXTG and 
LPXSG.68 These mutants were isolated after nine rounds of yeast display screening 
using a novel competition assay to select for mutants with narrow substrate 
specificity rather than substrate promiscuity. Therefore, the evolved mutants not only 
recognized substrates that differed from LPXTG, but also exhibited substantially 
reduced activity toward the original LPXTG motif recognized by wild type SrtAStaph. 
Using this substrate selectivity, the authors were able to demonstrate that their 
evolved sortases could be used to selectively pattern surfaces, as a means for the 
dual labeling of the N- and C-termini of the same protein target, and to covalently 
modify the human plasma protein fetuin A, which naturally contains a LPXSG motif 
near its C-terminus.  
A second strategy for expanding the substrate scope of sortase-mediated 
protein chemistry that has received relatively little attention concerns the use of 
naturally occurring sortase homologs. As described above, sortase homologs have 
been identified across a range of bacterial species. Intriguingly, many of these 
homologs are predicted to recognize substrates that differ from the LPXTG motif 
recognized by SrtAStaph.40 However, to date only two alternate homologs have been 
explored in the context of protein modification. Sortase A from Streptococcus 
pyogenes (SrtAStrep) has seen limited use for protein labeling and notably has the 
ability to recognize both LPXTG and LPXTA motifs.70 Due to this variation in 
substrate scope, SrtAStrep has provided a method for generating modified proteins 
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containing multiple labels attached to the protein N- and C-termini.52 In addition to 
SrtAStrep, a single report on the ability of sortase A from Lactobacillus plantarum 
(SrtAPlant) to generate labeled proteins through recognition of a LPQTSE sequence 
has also appeared, however, no evidence was provided concerning the efficiency of 
this transformation.71   
Overall, there is tremendous potential to utilize naturally occurring sortase 
homologs as a means for expanding the scope of sortase-based protein 
engineering. However, in order to do so the transpeptidation activity of each enzyme 
must be duplicated in vitro. A critical component of this involves determining the in 
vitro substrate preferences of each enzyme. In this regard, genomic information 
coupled with bioinformatics provides important insights for predicting the substrate 
specificities of different sortase homologs. Multiple algorithms have been designed 
to identify putative sortase substrates from genomic information.30,32,40,72 The most 
recent of these, the CW-PRED2 algorithm, is publicly available and has been used 
to predict sortase substrates from 177 bacterial genomes. In the case of SrtAStaph, 
15-21 substrates were predicted for each of 13 distinct strains.40 Figure 9 provides a 
graphical representation (generated using WebLogo3)73 of amino acid preferences 
across the LPXTG motif in all predicted substrates for SrtAStaph, including one 
additional residue C-terminal to the LPXTG core. A clear preference for leucine (L), 
proline (P), threonine (T), and glycine (G) was observed in positions 1, 2, 4, and 5 
with the only variation being the presence of LPXAG in ~10% of predicted 
substrates. The identity of the “X” residue in position 3 varied, though most predicted 
substrates possessed a charged amino acid in this position. A strong preference 
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was not predicted for position 6.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Predicted consensus sequence for the substrate motif of SrtAStaph. Substrate was identified 
using the CW-PRED2 prediction tool, and the graphic was generated using WebLogo3. The figure 
reflects bioinformatics predictions and the text reflects experimental data.  
 
Along with these bioinformatics predictions, the substrate preferences of 
SrtAStaph have also been determined experimentally using discrete peptide 
libraries.64,74,75 While the experimentally determined substrate preferences of 
SrtAStaph are largely consistent with predictions, important differences were observed 
that have proven critical to maximizing the utility of SrtAStaph for protein modification. 
The most striking of these is that there is a significant enhancement in the rate of in 
vitro transacylation when glycine is present in position 6.74 Interestingly, glycine is 
present in only ~10% of the predicted substrates for SrtAStaph at this position. At 
present, the LPXTGG motif is the standard for protein modification using wild type 
SrtAStaph. A more exhaustive study was conducted by Kruger et al. in which a library 
of peptides was synthesized representing nearly all possible amino acids at each of 
1 2 3 5 6 4 
SrtAstaph 
cleavage 
site 
1 
0.5 
0 
P
ro
b
a
b
ili
ty
  
G strongly 
preferred 
M,Y,L,Q,N 
preferred 
T preferred, 
A,S,L,V tolerated 
Position  
Number 
 16 
 
the five positions of the LPXTG motif.74 Substrate used in this approach had the 
general structures DNP-AXPETG, DNP-ALXETG, DNP-ALPXTG, DNP-LPETXG 
and DNP-LPETX (DNP = 2,4-dinitrophenyl, X = any amino acid except cysteine). 
The ability of wild type SrtAStaph to catalyze an in vitro transpeptidation was then 
evaluated and the results were monitored by HPLC. While results were overall 
consistent with the LPXTG specificity of SrtAStaph, important features of SrtAStaph 
reactivity were observed that were not accurately predicted by bioinformatics. 
Specifically, a preference for M, Y, L, Q, or N in position 3 was identified by studying 
the initial velocity of reactions on peptide substrates. These residues were not 
prevalent in the predicted substrates for SrtAStaph, where the majority of sequences 
contained a charged E, D, or K residue. SrtAStaph was also somewhat flexible in 
terms of the residue in position 4. While threonine was favored, SrtAStaph was also 
shown to cleave peptide substrates with A, S, V, or L in this position, albeit at a 
reduced rate.  Notably, only alanine is predicted to occur in natural substrates of 
SrtAStaph. These data suggest that SrtAStaph could be used to perform transacylations 
on substrates outside the canonical LPXTG motif, which further expands the utility of 
this method. Indeed, an LPXAG motif has recently been exploited to modulate the 
rate of self-cleavage in a SrtAStaph fusion construct for use as a new recombinant 
protein purification strategy.  
In total, the comparison between the predicted substrates for SrtAStaph and the 
experimentally determined substrates for this enzyme indicates that the true 
substrate scope of this enzyme was not accurately identified from bioinformatics 
predictions. This clearly indicates the need for experimentally profiling the substrate 
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specificities of different sortase homologs as a means for expanding the substrate 
scope of this technology. This thesis describes a strategy for experimentally profiling 
the in vitro substrate preferences of multiple sortase homologs. To expedite 
substrate screening, we have developed a two-stage process that begins with 
parallel screening of mixed synthetic peptide pools generated using isokinetic amino 
acid couplings. This information was then used to guide the synthesis of discrete 
peptide substrates for quantitatively evaluating sortase homolog reactivity. Using this 
approach, we have profiled the substrate preferences of ten sortase subclass A 
homologs, many of which had not been studied experimentally. We have further 
acquired preliminary evidence that different substrate preferences of alternate 
sortase homologs can be exploited for the synthesis of naturally occurring cyclic 
plant proteins. Overall, we have identified sortase homologs that recognize 
numerous variations of the standard SrtAStaph motif, and have compiled substrate 
preference data that will be valuable for the continued development of these 
enzymes as tools for site-specific protein modification.   
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2. Profiling Sortase Substrate Scope 
2.1 Expression of Sortase Subclass A Homologs 
 Our efforts to explore the substrate preferences of naturally occurring sortase 
homologs began with the cloning and expression of ten sortase subclass A 
enzymes. The decision to focus on this subclass is based on the fact that these 
enzymes are predicted to process multiple proteins in vivo through recognition of a 
small substrate motif.25 We hypothesized that these enzymes will show similar 
promiscuity in vitro, and thus serve as useful tools for modifying a range of proteins 
that contain the proper substrate sequence. The selected enzymes, predicted 
substrate sequences based on bioinformatics predictions, and predicted amine 
nucleophile structures are listed in Table 1. Substrate motifs were based on all 
predicted substrates for each particular organism identified using CW-PRED2, and 
in all cases a preference for the LPXTG motif was anticipated.30,40 Nucleophile 
structures were based on the peptidoglycan structure of each organism.30,76 With the 
goal of characterizing enzymes that would be Orthogonal to the reactivity of 
SrtAStaph, we selected sortases with unique variations in lipid II structure. These 
included enzymes that were predicted to accept N-terminal alanine residues (entries 
1-2,9), D-amino acids (entries 3-6), the ε-amine of lysine residues (entries 7-9), and 
serine residues (entry 10).  
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Table 1. Predicted substrate sequences and nucleophile preferences of ten sortase subclass A 
homologs. Substrates were identified using the CW-PRED2 prediction tool, and the graphic was 
generated using WebLogo3 
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Sortase expression vectors were obtained from a variety of sources. Genes 
encoding SrtAStaph, SrtAAnth, SrtAPneu, SrtAFae, and SrtAMono were obtained via 
commercial gene synthesis or were provided by other academic labs. SrtAPlant and 
SrtAStrep were cloned as maltose binding protein (MBP) fusions to assist with 
solubility and purification.  SrtASuis and SrtAOralis were originally obtained as GeneArt 
Strings (Invitrogen) and subcloned into a commercial pJ414 vector (DNA 2.0). In all 
cases, the N-terminal transmembrane region of each enzyme was truncated to yield 
soluble catalytic fragments. All sortases were also fused to His6 tags at their N-
terminus to facilitate purification. With the necessary plasmids in hand, we then 
expressed and purified each sortase from E. coli BL21(DE3) using standard 
molecular biology techniques. All enzymes were purified using Ni-NTA 
chromatography. Following purification, SDS-PAGE revealed bands with appropriate 
molecular weights for each enzyme. SDS-PAGE also revealed that sortases were 
isolated with good to excellent purity as shown in Figure 10. These enzymes were 
used without further purification. 
 
 
 
 
 
 
 
 
 
 
Figure 10.  SDS-PAGE analysis of Sortase A homologs expressed and purified from E. coli. 
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2.2 Design and Synthesis of Isokinetic Peptide Library. 
As described above in section 1.4, synthetic peptide substrates have revealed 
important features of the in vitro reactivity of SrtAStaph that in certain cases were not 
predicted by bioinformatics studies. We therefore sought to apply a similar strategy 
to characterize our alternate sortase homologs. However, recognizing that the 
individual synthesis of numerous synthetic peptides would be costly and time 
consuming, we designed a strategy to allow for the simultaneous screening of 
multiple potential substrates as a way to rule out unreactive sequences. Our 
approach was based on the use of isokinetic amino acid couplings employed during 
solid-phase peptide synthesis. Briefly, isokinetic couplings involve the use of multiple 
amino acids in solid-phase couplings to produce mixtures of peptides in 
approximately equal quantities.77 This is achieved by using certain ratios of amino 
acid building blocks that have been experimentally shown to couple at approximately 
the same rate during solid-phase peptide synthesis. In this way, pools of peptides 
can be generated from single solid-phase syntheses. This strategy has shown 
success in the synthesis of peptide libraries for a range of biochemical studies.77-79 
We designed and synthesized four peptide pools for the initial screening of 
our sortase homologs. As shown in Figure 11, each pool consisted of six-residue 
peptide substrates in which either position 1, 2, 4 or 5 of the standard SrtAStaph 
LPXTG motif was randomized using an isokinetic amino acid coupling. Substrates 
were also designed to contain a C-terminal dinitrophenyl (DNP) fluorescence 
quencher and a N-terminal 2-aminobenzoic acid (Abz) fluorophore. These functional 
groups provided two important features. First, the DNP moiety provided a distinct 
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chromophore for estimating substrate concentrations in solution. Second, this 
fluorophore-quencher pair has been utilized to provide a simple visual indicator of 
sortase activity.80,81 When the substrates are fully intact, Abz fluorescence is 
quenched by the proximity of DNP. However, when the substrate is cleaved, the 
removal of the quencher results in a significant increase in observed fluorescence.   
The overall synthetic strategy for the Abz-LPATXG-K(DNP) pool (pool 5) is 
illustrated in Figure 11. A similar strategy was also used to assemble pools 1, 2, and 
4. Peptides were synthesized on commercial Rink Amide 4-Methylbenzhydrylamine 
(MBHA) Resin. Following removal of the initial Fmoc protecting group, the C-terminal 
amino acid was coupled using HBTU as a coupling agent. Repeated cycles of Fmoc 
deprotection and amino acid coupling were then used to assembly each substrate 
pool. The isokinetic couplings were achieved using a published ratio of Fmoc 
protected amino acids.77,78 Notably, the mixtures we employed excluded cysteine 
and used norleucine (Nle) in place of methionine to avoid complications from 
disulfide bond formation and thioether oxidation, respectively. Each pool therefore 
contained 19 different peptides. After assembly, peptide pools were cleaved from the 
resin using a standard 95:3:2 TFA/TIPS/H2O cleavage cocktail. Pools were then 
precipitated from cold diethyl ether, and stock solutions were prepared using the 
absorbance of the DNP chromophore to estimate overall peptide concentrations.  
Each peptide pool was analyzed by LC-ESI-MS (Table 2). As expected, 
masses consistent with the presence of all substrate variants were observed for 
each peptide pool. It should be noted that in the case of leucine, isoleucine, and 
norleucine the masses of the associated peptides were identical. Therefore, while 
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appropriate masses were observed, it was not possible to unambiguously confirm 
the presence of each isomer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Example solid-phase synthetic route for generating pool 5 Abz-LPATXG-K(DNP). Solid 
circle = solid support 
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Table 2. LC-ESI-MS detection of individual sequences in peptide pools 1, 2, 4, and 5. 
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2.3 Substrate Screening using LC-ESI-MS  
With all substrate pools in hand, we turned our attention to evaluating the 
reactivity of each sortase A homolog in a model in vitro transpeptidation reaction. 
Using pool 5 (Abz-LPETXG-K(DNP)), we developed a standard set of reaction 
conditions for screening each sortase homolog (Figure 12). These conditions 
included 25 μM sortase homolog, 200 μM total peptide concentration, and 10 mM 
hydroxylamine hydrochloride in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+. 
As indicated above, Ca2+ is a necessary cofactor for SrtAStaph activity, and therefore 
it was included in all assays. Hydroxylamine was also included at high 
concentrations to serve as a general strong nucleophile capable of breaking down 
the thioester-linked acyl enzyme intermediate. The use of hydroxylamine for this 
purpose has been demonstrated in previous work describing sortase in vitro 
reactivity. Screening reactions were incubated for 24 h at RT. As shown in Figure 
12, depending on the substrate specificity of each sortase homolog, screening 
reactions with pool 5 were expected to yield up to 20 possible reaction products. 
This included a single transpeptidation product, and up to 19 distinct smaller 
fragments containing the position randomized using isokinetic amino acid coupling 
(Figure 12a). Similar product distributions were expected for screening reactions 
employing peptide pools 1, 2, and 4 (Figure 12b). In these cases, the position of the 
randomized position would lead to 19 different transpeptidation products, and only a 
single fragment containing the DNP chromophore. 
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Figure 12.  a) In vitro isokinetic library screening reaction scheme for pools 5. b) In vitro isokinetic 
library screening reaction scheme for pools 2, 3, and 4. All reaction conditions include 25 μM sortase 
homolog, 200 μM total substrate concentration, and 10 mM hydroxylamine in aqueous Tris buffer (pH 
7.5) containing 10 mM Ca2+. All reactions were run at room temperature for 24 hours followed by 
analysis using ESI-LC-MS. 
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LC-ESI-MS was employed to decipher the product mixtures obtained from 
each screening reaction. Representative data obtained from substrate pool 5 and 
SrtAStaph is depicted in Figure 13. Direct injection of this crude reaction mixture 
produced a complex total ion current (TIC) chromatogram revealing numerous peaks 
in the mass range of 400 m/z to 1250 m/z. In order to identify specific reaction 
products, the extract ion function available in Analyst 1.4.2 software was utilized to 
restrict the mass range to certain regions of interest. For example, the reaction of 
SrtAStaph with substrate pool 5 was anticipated to yield a single transpeptidation 
product consisting of the Abz-LPAT fragment of the initial substrate pool covalently 
linked to hydroxylamine. The calculated mass for the M+H+ ion of this product was 
535.3 Da. When the TIC was restricted to masses in the range of 535 to 536 Da, a 
clear peak emerged from the background with a retention time of approximately 5 
minutes (Figure 13b). The corresponding mass spectrum of this peak revealed a 
strong signal at 535.6 Da, confirming the presence of the expected transpeptidation 
product.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. LC-ESI-MS library screening for pool 5 Abz-LPATXG-K(DNP) with SrtAAtaph. a) TIC of the 
reaction of pool 5 with SrtAStaph. b) Extraction of expected transpeptidation product mass 535-536 Da, 
and mass spectrum revealing the expected signal at 535.6 Da. c) Mass extraction of GG-K(DNP) 
fragment in the range of 426-427 Da, and mass revealing expected signal at 426.4 Da. d) Mass 
extraction of AG-K(DNP) fragment in the range of 440-441 Da showing no signal corresponding to 
this product. 
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Mass extractions were then performed for each of the 19 possible fragments 
arising from isokinetic coupling at the fifth position of the original LPXTG motif. As 
shown in Figure 13c, a signal corresponding to a GG-K(DNP) fragment was clearly 
evident in the data set. When the TIC was extracted for ions in the range of 426-427 
Da, a clear peak at approximately 4 minutes was observed, and the corresponding 
mass spectrum revealed an intense peak at 426.4 Da, which was consistent with the 
calculated mass for the M+H+ ion of GG-K(DNP). Therefore, this suggested that 
SrtAStaph was able to process a LPATGG motif. In contrast to GG-K(DNP), when the 
TIC was extracted for ions appropriate for a AG-K(DNP) fragment, no signal was 
observed (Figure 13d). This suggested that SrtAStaph was unable to catalyze a 
transpeptidation reaction involving a LPATAG substrate. Negative results were also 
obtained for the remaining XG-K(DNP) fragments involving amino acids other than 
glycine. Overall, these data suggested that SrtAStaph was only able to recognize 
substrates containing glycine in the fifth position, which was fully consistent with all 
previous reports on the substrate preferences of this enzyme.  
The screening and data analysis strategy described above was then applied 
to all ten sortase homologs paired with each of the four synthetic peptide pools 
(Table 3). It should be noted in the data sets in Table 3 that fragments containing 
leucine, isoleucine, and norleucine produced fragments with identical molecular 
weights, and therefore we were unable to unambiguously determine whether all or a 
subset of these residues were tolerated in certain cases. In addition, attempts were 
made to extract quantitative data concerning reaction efficiency from LC-ESI-MS 
data sets. However, efforts to generate appropriate calibration curves resulted in 
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inconsistent ion intensity values, and ultimately we settled on a qualitative 
interpretation of the mass spectral data.  
 
Table 3: LC-ESI-MS screening for libraries in position 1, 2, 4, and 5. Filled boxes indicate positive hits 
identified by LC-ESI-MS. Gray boxes match bioinformatics predictions. Red boxes represent activity 
that was not predicted by bioinformatics. 
 
 
 
 
 
 
 
 
 
 
 
In examining the reactivity profiles for each sortase homolog, we were 
encouraged by the fact that the pattern observed for SrtAStaph showed very good 
consistency with previous reports on the substrate specificity of this enzyme.74 
Specifically, SrtAStaph was exclusively selective for glycine (G) in position 5, and 
further showed the ability to accept threonine (T), alanine (A), serine (S), valine (V), 
and potentially norleucine / leucine / isoleucine (Nle/L/I) in position 4. These results 
exactly mirror the substrate specificity data reported by Kruger et al.74 in which the 
authors utilized individual peptides to probe SrtAStaph substrate specificity. Our 
observed reactivity also showed very good consistency for positions 1 and 2. Kruger 
reported that SrtAStaph accepted leucine (L) and methionine (M) in position 1, 
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whereas we observed reactivity with norleucine / leucine / isoleucine (Nle/L/I) and 
phenylalanine (F). Notably, norleucine (Nle) was included in our library as an 
isosteric mimic of methionine. With regard to position 2, Kruger reported a strong 
preference for proline (P) and trace activity with alanine (A). Our screening revealed 
an exclusive preference for proline (P) in position 2, and our failure to detect alanine 
(A) is likely due to the fact that this is a poor substrate for SrtAStaph.  
We were struck by the range of substrate promiscuity exhibited by different 
sortase homologs. Clear trends included the fact that charged residues (K, R, H, D, 
and E) were poorly tolerated across all enzymes and all positions. In addition, 
proline was only accepted at the expected location in position 2 of the substrate 
motif. Apart from these, interesting deviations from the standard LPXTG motif were 
observed, and were primarily centered on positions 4 and 5. Homologs from S. 
pneumonia and L. monocytogenes seemed to exhibit the greatest range of substrate 
tolerance. Numerous examples of reactivity were detected that where not predicted 
by bioinformatics. This included the ability of certain homologs to accept 
phenylalanine (F) in position 1 and valine (V) in position 2. With respect to position 4, 
new reactivity was observed for alanine (A), serine (S), valine (V), phenylalanine (F), 
norleucine / leucine / isoleucine (Nle/L/I). Position 5 yielded the most unexpected 
results, with certain homologs exhibiting the ability to accept alanine (A), serine (S), 
valine (V), phenylalanine (F), tyrosine (Y), tryptophan (W), asparagine (N), glutamine 
(Q), and norleucine / leucine / isoleucine (Nle/L/I). 
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2.4 Substrate Validation using Discrete Peptides. 
 Encouraged by the putative substrate hits from our LC-ESI-MS screening 
efforts, we next turned our attention to quantitatively validating these results using 
individually synthesized peptide substrates. Our primary motivation for pursuing 
these studies was the fact that our mass spectrometry screening did not allow for 
quantitative evaluation of reaction progress for each substrate. In addition, our initial 
peptide pools did not allow for distinguishing between substrates that contained 
leucine, isoleucine, or norleucine and individually synthesized peptides would allow 
a comparison between these residues. Finally, our libraries also excluded cysteine 
to avoid complications from disulfide bond formation, and therefore we sought to 
include this amino acid in our screening efforts.  
Using solid-phase peptide synthesis, we synthesized discrete peptide 
substrates covering all of the putative substrate hits detected in our mass 
spectrometry screening efforts. A representative synthetic scheme for the 
preparation of a Abz-LPATSG-K(DNP) is illustrated in Figure 14.  
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Figure 14: Example solid-phase synthetic route for generating discrete peptide Abz-LPATSG-K(DNP) 
 
All peptides were synthesized using commercially available Rink Amide 
MBHA resin. Repeated cycles of Fmoc deprotection and amino acid coupling using 
HBTU were performed to assemble the desired peptide sequences. The majority of 
peptides were cleaved from the resin using a standard 95:2.5:2.5 TFA/TIPS/H2O 
cleavage cocktail. DTT was added to this mixture for cysteine-containing peptides to 
maintain thiols in their reduced stated. All peptides were purified to homogeneity 
using RP-HPLC and the identity of each peptide was confirmed by LC-ESI-MS 
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(Figure 15). A total of 28 individual peptides were synthesized. While this is a 
substantial number, it highlights the value of the isokinetic library pre-screening 
approach that was employed in section 2.3. Had the isokinetic pools not been 
employed, a total of 80 individual sequences would have been required to cover the 
same sequence described here.  
With the individual peptides in hand, we proceeded to monitor the ability of 
each sortase homolog to catalyze a model transacylation with each substrate. In 
these studies, even if an enzyme did not show reactivity toward a particular 
substrate in our mass spectrometry screen, it was included as a negative control. All 
model transacylation reactions were performed using 25 μM sortase homolog, 200 
μM peptide, and 10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 
mM Ca2+. Reactions with cysteine-containing substrates were supplemented with 
100 mM DTT to prevent complications from disulfide bond formation. All reactions 
were incubated at room temperature for 24 hours following by analysis using 
analytical RP-HPLC.  
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Figure 15.  Characterization of all discrete substrates with RP-HPLC and LC-ESI-MS.  
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Figure 15 (con’t).  Characterization of all discrete substrates with RP-HPLC and LC-ESI-MS. 
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A representative data set for the reaction of Abz-LPATSG-K(DNP) with 
SrtAPneu is given in Figure 16. This reaction was expected to yield the desired 
transpeptidation product, a small SG-K(DNP) fragment, as well as potentially a 
hydrolytic product arising from nucleophilic attack of water on the acyl enzyme 
intermediate. Using the absorbance of the DNP chromophore, the reaction 
conversion was estimated by comparing peak areas for the input substrate and the 
C-terminal SG-K(DNP) fragment detected in the 365 nm chromatogram. A decrease 
in the input peptide single and the appearance of a new fragment peak was clearly 
evident relative to a control reaction lacking SrtAPneu. Similar reaction profiles were 
obtained for the remaining combinations of sortases and substrates, and these 
results are described below. 
 
 
 
 
 
 
 
Figure 16.  a) Example transpeptidation reaction with Abz-LPATSG-K(DNP) and SrtAPneu. Reaction 
conditions: 25 μM sortase homolog, 200 μM peptide, and 10 mM hydroxylamine in aqueous Tris 
buffer (pH 7.5) containing 10 mM Ca2+. b) RP-HPLC characterization of in vitro transpeptidation.  
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Starting with the 1st position of the substrate motif, a total of five peptides 
were analyzed (Figure 17). As expected, leucine (L) was well tolerated in this 
position, with all but two enzymes (SrtAFae and SrtAPlant) showing significant reaction 
conversion over the course of 24 h. Multiple enzymes also exhibited the capacity for 
processing substrates containing isoleucine (I) and / or norleucine (Nle), with the 
most reactive enzymes being SrtAStaph, SrtAMono, and SrtAPneu, and SrtAStrep.  These 
results are particularly notable as none of the predicted substrates for these 
enzymes possess isoleucine or methionine, the latter being mimicked in our case by 
the isosteric residue norleucine. Reactivity with phenylalanine (F) in position 1 was 
more limited, with only SrtAPneu and SrtAStrep showing significant reaction conversion. 
Finally, substrates containing cysteine in position 1 were essentially non-reactive, 
suggesting that a hydrophobic, sterically bulky residue is required in position 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Activity of sortase A homologs with discrete peptides in position 1. All reactions include 25 
μM sortase homolog, 200 μM Abz-XPATGG-K(DNP) (X= F, Nle, I, L, C), and 10 mM hydroxylamine in 
aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+. Reactions with cysteine-containing substrates 
were supplemented with 100 mM DTT to prevent complications from disulfide bond formation. All 
reactions were incubated at room temperature for 24 hours following by analysis using analytical RP-
HPLC. Values shown represent % reaction conversion are the average of three trials. In all cases, the 
standard deviation was ≤ 10%. 
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In addition to simply monitoring reaction conversion by RP-HPLC, we also 
analyzed a subset of these model reactions by LC-ESI-MS to verify the formation of 
the expected reaction products. Specifically, reactions exhibiting greater than 25% 
conversion were analyzed and the observed masses for all relevant species are 
given in Table 5. All anticipated reaction components were clearly identified. In 
addition to the presence of the expected transpeptidation product in each reaction, 
trace levels of the competing hydrolysis product were also observed. However, using 
peak intensity ratios derived from the corresponding mass spectra, the formation of 
the desired transpeptidation products was highly favored in all cases (Table 5, due 
to the extensive size of this table this data is presented at the end of this chapter 
beginning on page 51-53).  
Moving on to substrates focused on position 2 of the substrate motif, three 
sequences were analyzed (Figure 18). As in the case of position 1, SrtAPlant and 
SrtAFae showed little reactivity with all substrates tested. For all other homologs, 
proline (P) was well tolerated in position 2, which is consistent with substrate 
predictions for these enzymes. Switching to valine (V), only SrtAPneu, SrtASuis, and 
SrtALac yielded significant product conversion. Finally, the inclusion of cysteine (C) 
gave modest levels of conversion for most enzymes, with the best results observed 
using SrtASuis (~65% conversion).  
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Figure 18. Activity of sortase A homologs with discrete peptides in position 2 using RP-HPLC. All 
reaction conditions include 25 μM sortase homolog, 200 μM Abz-LXATGG-K(DNP) (X= P, V, C), and 
10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+. Reactions with 
cysteine-containing substrates were supplemented with 100 mM DTT to prevent complications from 
disulfide bond formation. All reactions were incubated at room temperature for 24 hours following by 
analysis using analytical RP-HPLC. Values shown represent % reaction conversion are the average 
of three trials. In all cases, the standard deviation was ≤ 10%. 
 
 
LC-ESI-MS was again employed for reactions generating 25% reaction 
conversion or higher (Table 5), and as in the case of the position 1 substrates, all 
reaction products were readily identified, and the formation of the desired 
transpeptidation products was strongly favored versus hydrolysis.  
For sequences involving position 4, a much wider range of substrate 
promiscuity was observed. In addition to the expected ability of most homologs to 
accept threonine (T), multiple enzymes were found to tolerate cysteine (C), valine 
(V), phenylalanine (F), norleucine (Nle), leucine (L), serine (S), and alanine (A). 
Isoleucine (I) was observed to be completely unreactive in this position. As 
described above, the ability of different sortase homologs to accept many of these 
residues contrasted with the predicted substrate selectivity of these enzymes. This 
was most striking in the case of serine, valine, phenylalanine, leucine, and 
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norleucine, where only SrtALac was predicted to exhibit any reactivity toward a subset 
of these residues (Figure 19).  
 
 
 
 
 
 
 
Figure 19.  Activity of Sortase A homolog with discrete peptides in position 4 using RP-HPLC. All 
reaction conditions include 25 μM sortase homolog, 200 μM Abz-LPAXGG-K(DNP) (X= A, S, L, I, Nle, 
F, V, T, C), and 10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+. 
Reactions with cysteine-containing substrates were supplemented with 100 mM DTT to prevent 
complications from disulfide bond formation. All reactions were incubated at room temperature for 24 
hours following by analysis using analytical RP-HPLC. Values shown represent % reaction 
conversion are the average of three trials. In all cases, the standard deviation was ≤ 10%. 
 
 
Once again, LC-ESI-MS confirmed the presence of all expected reaction 
products for reactions reaching greater than 25% conversion, and transpeptidation 
continued to be favored over substrate hydrolysis (Table 5).  
Finally, we assessed the reactivity of thirteen substrates possessing different 
residues in position 5. This group represented the largest and most diverse set of 
substrates analyzed. While four substrates (those possessing Q, W, I, and Nle) 
failed to show significant reactivity, we were able to identify at least one sortase 
homolog that was able to catalyze a transpeptidation reaction with the remaining 
nine sequences. This data set was particularly noteworthy in the way the reactivity of 
most sortase homologs contrasted with that of SrtAStaph. As shown in Figure 20, 
SrtAStaph was exclusively selective for glycine (G) in position 5. Our data indicated 
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that by simply employing a sortase homolog, we were now able to execute 
transpeptidations on a significantly wider range of sequences. In some cases, the 
pairing of substrate to enzyme was very specific. For example, SrtAPneu was the only 
homolog observed to react with LPATVG and LPATLG, and only two homologs 
(SrtAPneu and SrtAMono) were found to react with LPATFG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Activity of sortase A homologs with discrete peptides in position 5 using RP-HPLC. All 
reaction conditions include 25 μM sortase homolog, 200 μM Abz-LPATXG-K(DNP) (X= A, G, S, V, N, 
F, W, Y, Q, I, L, Nle, C), and 10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 mM 
Ca2+. Reactions with cysteine-containing substrates were supplemented with 100 mM DTT to prevent 
complications from disulfide bond formation. All reactions were incubated at room temperature for 24 
hours following by analysis using analytical RP-HPLC. Values shown represent % reaction 
conversion are the average of three trials. In all cases, the standard deviation was ≤ 10%. 
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As described above, mass spectrometry was used to further analyze 
reactions that generated greater than 25% conversion. In the majority of cases, the 
expected reaction products were readily identified (Table 5). However, in the case of 
reactions employing LPATFG, LPATWG, and LPATYG with either SrtAPneu or 
SrtAMono, we observed a second minor transpeptidation product involving an offset 
cleavage between the aromatic residue and the glycine residue of the substrate 
sequence (Figure 21). This product was readily identified by LC-ESI-MS, and was 
formed in addition to the expected transpeptidation product involving cleavage C-
terminal to the threonine residue. In some instances, the offset transpeptidation 
product represented >10% of the total transpeptidation product mixture. Specifically, 
in the case of the reaction of LPATYG with SrtAPneu, the ratio of offset cleavage to 
standard transpeptidation was 1:7. This phenomenon was not investigated further in 
this work. However, it was clear that this reactivity was restricted to SrtAPneu, and 
SrtAMono in combination with substrates that possesses bulky aromatic residues in 
position 5 of the sortase substrate motif.  
 
 
 
 
 
 
Figure 21.  Example transpeptidation reaction with Abz-LPATYG-K(DNP) and SrtAPneu.  Reaction 
conditions include 25 μM sortase homolog, 200 μM peptide, and 10 mM hydroxylamine in aqueous 
Tris buffer (pH 7.5) containing 10 mM Ca2+. Reactions incubated at room temperature for 24 hours 
following by analysis using LC-ESI-MS.  
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Having completed our initial evaluation all discrete peptides under conditions 
that directly mirrored our mass spectrometry screen, we next sought to investigate 
whether certain combinations of enzyme and substrate could be optimized to 
improve reaction conversion. This was motivated by the fact that certain 
transpeptidations gave only modest conversion, and in order to utilize these 
reactions in protein modification, these conversions should ideally be increased. In 
the case of SrtAStaph, there is substantial literature precedent showing that the rate of 
in vitro transpeptidation can be improved by simply increasing enzyme concentration 
and raising the reaction temperature.70,82,83 Therefore, we selected a total of five 
sequences (Abz-LPATVG-K(DNP), Abz-LPATNG-K(DNP), Abz-FPATGG-K(DNP), 
Abz-IPATGG-K(DNP), and Abz-LPAFGG-K(DNP)) and evaluated the effect of 
increasing temperature and enzyme concentration. As in the studies described 
above, reaction progress was monitored by RP-HPLC. The results of these 
optimizations are given in Table 4.  
 
Table 4. Optimized Reactions with SrtA homologs by increasing temperature and 
enzyme concentration. The numbers illustrate % cleavage of substrate by SrtA. 
 
Substrate Sortase 25 uM enzyme 25 uM enzyme, 37 oC 50 uM enzyme, 37 oC 
LPATVG SrtAPneu 39 59 76 
LPATNG SrtAPneu 48 76 84 
LPATNG SrtASuis 44 68 83 
LPATNG SrtAMono 35 37 55 
FPATGG SrtApneu 32 60 71 
LPAFGG SrtAMono 32 64 73 
LPAFGG SrtApneu 60 92 89 
LPAFGG SrtALac 17 50 81 
IPATGG SrtAStaph 54 77 89 
IPATGG SrtAMono 43 69 85 
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In all cases reaction conversions were improved. Both increased temperature 
and higher enzyme loading had positive effects, allowing the conversion of all but 
one enzyme/substrate combination to reach 70% conversion or higher. A 
representative example of RP-HPLC data for the optimization of the reaction of 
IPATGG with SrtAMono is given in Figure 22, revealing a substantial increase in 
reaction conversion when additional enzyme and higher temperatures were 
employed. Overall, these results demonstrated that conversion could be readily 
enhanced by adjusting simple reaction variables, and provided evidence that even 
reaction combinations that showed minimal cleavage activity in our initial studies 
(see Figures 17, 18, 19, and 20) have the potential to serve as efficient 
transformations for protein structure manipulation.  
 
 
 
 
 
 
 
 
Figure 22. a) Example transpeptidation reaction with Abz-IPATGG-K(DNP) and SrtAmono. b) sample 
RP-HPLC reaction with SrtAPneu with standard and modified conditions. Standard reaction conditions 
include 25 μM sortase homolog, 200 μM peptide, and 10 mM hydroxylamine in aqueous Tris buffer 
(pH 7.5) containing 10 mM Ca2+ incubated at room temperature for 24 hours and analyzed using 
analytical RP-HPLC. Optimized reactions condition include 50 μM sortase homolog, 200 μM peptide, 
and 10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+ incubated at 37 
degrees Celsius for 24 hours and analyzed using analytical RP-HPLC.  
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Summary 
In this chapter we have described a process for profiling the substrate 
preferences of ten different sortase A homologs with the goal of expanding the 
scope of substrates for use in sortase-mediated protein modification strategy. 
Through the use of peptide pools generated using isokinetic amino acid couplings, 
we were able to conduct a rapid pre-screen to identify the most promising substrates 
for further analysis. Hits identified by mass spectrometry screening were then 
resynthesized and used to quantitatively assess the ability of different sortase 
homologs to process each substrate sequence. Overall, this has revealed a number 
of new substrate sequences with the potential for use in sortase-catalyzed protein 
engineering applications. Prior to this work, a total of 19 substrates had been 
reported that were processed by sortases described in the literature (Figure 23).64,67-
69,71,74,75 This included wild type SrtAStaph, evolved sortases, and natural homologs 
from S. pyogenes and L. plantarum. As a result of our efforts, we have expanded 
this set to include potentially 15 entirely new sequences motifs, and substantially 
improved the efficiency of transpeptidation involving previously reported substrate 
motifs (notably LPXTS, LPXVG, LPXLG, and FPXTG). While our work has focused 
on simple model transpeptidation reactions, we anticipate that further optimization of 
these enzyme / substrate pairs will enable new strategies for protein engineering.  
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Figure 23. Comparison of substrates discovered through previous studies and this study.  
In addition to the implications this work has for the expansion of sortase-
mediated protein modification, these studies also raise interesting questions 
concerning the biochemical basis for the substrate promiscuity exhibited by each 
enzyme. At present, a detailed explanation of these results involving the structure of 
each sortase homolog is difficult given that only a single NMR structure of a sortase 
subclass A homolog in complex with a structural mimic of its substrate has been 
reported.84 This complex, which consists of SrtAStaph in disulfide linkage with a LPAT 
peptide fragment, does provide some insight into our observed substrate selectivity 
(Figure 24a).84 
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First, with respect to positions 1 and 2 of the substrate motif, in general we 
found few instances where sortase homologs deviated from the expected selectivity 
for leucine (L) and proline (P). In the case of position 1, the only other residues 
tolerated were similar to leucine in that they were also bulky and hydrophobic (I, Nle, 
and F). In the published structure of the SrtAStaph enzyme substrate complex, the 
leucine side chain was shown to form significant hydrophobic contacts with the 
substrate-binding groove, and our data suggests that similar interactions must be 
present in the substrate binding sites of the sortase homologs evaluated here. For 
position 2, we generally observed a strong preference for proline (P). Structural 
characterization (Figure 24a), as well as biochemical data, suggests that proline 
creates a unique kink in the substrate motif, allowing the sorting substrate to adopt 
an L-shaped conformation in the substrate binding groove of SrtAStaph.84,85 Again, our 
data is consistent with a kinked substrate being preferred by the sortase homologs 
studied here, and this conformation is likely favored by the presence of proline.  
 
 
 
 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. a) NMR structure of SrtAStaph in complex with a LPAT fragment (PDB ID: 2KID).84 b) Model 
of SrtAPneu generated by one-to-one threading with SrtAStaph.86 c) Overlay of SrtAStaph and SrtAPneu 
model. 
 
Moving on to position 4, overall we observed significantly greater substrate 
promiscuity that involved a number of residues other than the standard threonine 
residue. In the case of SrtAStaph, NMR characterization suggests that the threonine 
creates a steric wedge that lifts the β7/β8 loop of the enzyme away from the active 
site (Figure 24a).84 Interestingly, this interaction does not seem to involve distinct 
polar interactions with the threonine hydroxyl group and the sortase enzyme, but 
rather involves packing of the threonine methyl group against a tryptophan side 
chain. Depending on the size of the β7/β8 loop in each sortase homolog, we 
propose that a number of amino acid side chains could potentially create this steric 
interaction, thus resulting in the observed substrate promiscuity. In support of this 
interpretation, we also note that substrates containing glycine (LPXGG), which lacks 
a b c 
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a side chain, was shown to have no reactivity in both our work and the work of 
Kruger et al.74 
Finally, in the case of position 5 we observed the most striking deviations 
from the substrate preferences of SrtAStaph. While SrtAStaph was exclusively selective 
for glycine, we identified sortase homologs that were tolerant of a much wider range 
of residues. In particular, sortase homologs from S. pneumoniae and L. 
monocytogenes accepted the greatest range of residues in position 5. In the case of 
SrtAPneu, comparison with the structure of SrtAStaph in Figure 24b,c reveals unique 
structural features that may be involved with this substrate promiscuity. Using the 
one-to-one threading function available through the Phyre 2 Protein Recognition 
Server, we constructed a model of SrtAPneu.86 As expected, the threaded SrtAPneu 
structure shows significant similarity to SrtAStaph, however, the β7/β8 loop region of 
SrtAPneu was predicted to be significantly shorter. In the case of SrtAStaph, NMR 
perturbation studies have revealed that the β7/β8 loop participates in significant 
interactions with incoming glycine nucleophiles, and therefore also likely makes 
significant contacts with position 5 of the substrate sequence. Our hypothesis is that 
the reduced size of the β7/β8 loop in SrtAPneu creates a less sterically encumbered 
binding groove, which allows this enzyme to accommodate amino acids other than 
glycine in position 5. While not shown here, a similar reduction in β7/β8 loop size is 
predicted for SrtAMono. Going forward, the validation of these hypotheses will require 
more detailed structural characterization, ideally involving substrate mimics 
covalently bound to sortase homolog active sites.  
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Table 5. LC-ESI-MS confirmation of product masses for discrete peptide model reactions. 
 
 
Abz-XPATGG-K(DNP) Discrete Hits LC-ESI-MS Analysis 
 
 Substrate Fragment 
Transpeptidation 
Product 
Hydrolysis 
Product / 
Hydrolysis 
Ratio 
X = Sortase Calcd Obs Calcd Obs Calcd Obs Calcd Obs 
 
Nle Staph 927.4 927.9 426.2 426.4 535.3 535.5 520.3 520.6 173 
L Staph 927.4 927.6 426.2 426.3 535.3 535.4 520.3 520.3 15 
I Staph 927.4 927.9 426.2 426.3 535.3 535.6 520.3 520.5 108 
Nle Suis 927.4 927.8 426.2 426.3 535.3 535.5 520.3 520.4 34 
I Suis 927.4 927.9 426.2 426.4 535.3 535.6 520.3 520.5 31 
L Suis 927.4 927.6 426.2 426.3 535.3 535.4 520.3 520.4 26 
Nle Oralis 927.4 927.8 426.17 426.4 535.3 535.5 520.3 520.5 64 
L Oralis 927.4 927.5 426.2 426.3 535.3 535.3 520.3 520.3 31 
Nle Pneu 927.4 927.8 426.2 426.4 535.3 535.5 520.3 520.5 132 
I Pneu 927.4 927.8 426.2 426.4 535.3 535.5 520.3 520.5 215 
F Pneu 961.4 961.7 426.2 426.4 569.3 569.5 554.3 554.6 27 
L Pneu 927.4 927.6 426.2 426.2 535.3 535.5 520.3 520.3 28 
Nle Mono 927.4 927.8 426.2 426.3 535.3 535.5 520.3 520.5 75 
I Mono 927.4 927.9 426.2 426.3 535.3 535.6 520.3 520.5 70 
L Mono 927.4 927.5 426.2 426.2 535.3 535.4 520.3 520.3 16 
L Lactis 927.4 927.6 426.2 426.2 535.3 535.5 520.3 520.5 52 
Nle Strep 927.4 927.8  426.2  426.3 535.3 535.5  520.3 520.5   10 
I Strep 927.4 927.8 426.2 426.3 535.3 535.5 520.3 520.4 15 
F Strep 961.4 961.6 426.2 426.4 569.3 569.3 554.3 554.6 16 
L Strep 927.4 927.6 426.2 426.3 535.3 535.5 520.3 520.4 24 
L Anth 927.4 927.6 426.2 426.4 535.3 535.4 520.3 520.3 0 
 
 
 
 
Abz-LXATGG-K(DNP) Discrete Hits LC-ESI-MS Analysis 
 
Substrate Fragment 
Transpeptidation 
Product 
Hydrolysis 
Product / 
Hydrolysis 
Ratio 
X = Sortase Calcd Obs Calcd Obs Calcd Obs Calcd Obs 
 
C Staph 933.4  n.d. 426.2  n.d.  541.2  n.d.  526.2  n.d.   n.d.  
C Suis 933.4  n.d.  426.2  n.d.  541.2   n.d. 526.2   n.d.  n.d.  
V Suis 929.4 929.6 426.2 426.4 537.3 537.6 522.3 522.5 20 
C Pneu 933.4   n.d. 426.2   n.d. 541.2   n.d. 526.2  n.d.   n.d.  
V Pneu 929.4 929.5 426.2 426.4 537.3 537.5 522.3 522.6 29 
C Lactis 933.4  n.d.  426.2   n.d. 541.2  n.d.  526.2  n.d.    n.d. 
V Lactis 929.4 929.5 426.2 426.3 537.3 537.4 522.3 522.5 30 
C Strep 933.4   n.d. 426.2   n.d. 541.2   n.d. 526.2   n.d.   n.d. 
V Strep 929.4 929.6 426.2 426.5 537.3 537.5 522.3 522.6 4 
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Abz-LPAXGG-K(DNP) Discrete Hits LC-ESI-MS Analysis 
 
Substrate Fragment 
Transpeptidation 
Product 
Hydrolysis 
Product / 
Hydrolysis 
Ratio 
X = Sortase Calcd Obs Calcd Obs Calcd Obs Calcd Obs 
 
A Staph 897.4 897.6 426.2 426.6 505.3 505.7 490.3 490.6 3 
S Staph 913.4 913.7 426.2 426.4 521.3 521.4 506.3 506.6 46 
L Staph 939.5 939.8 426.2 426.4 547.3 547.6 532.3 532.9 17 
V Staph 925.5 926.0 426.2 426.4 533.3 533.8 518.3 518.7 5 
C Staph 929.4  n.d.  426.2  n.d.  537.2  n.d.  522.2  n.d.    n.d. 
A Suis 897.4 897.6 426.2 426.5 505.3 505.7 490.3 490.6 21 
S Suis 913.4 913.7 426.2 426.4 521.3 521.5 506.3 506.5 37 
L Suis 939.5 939.8 426.2 426.5 547.3 547.8 532.3 532.7 30 
C Suis 929.4   n.d. 426.2  n.d.  537.2   n.d. 522.2  n.d.    n.d. 
A Oralis 897.4 897.7 426.2 426.3 505.3 505.7 490.3 490.7 41 
L Oralis 939.5 939.8 426.2 426.5 547.3 547.6 532.3 532.8 27 
C Oralis 929.4   n.d. 426.2  n.d.  537.2  n.d.  522.2   n.d.  n.d.  
A Pneu 897.4 897.7 426.2 426.4 505.3 505.7 490.3 490.6 16 
S Pneu 913.4 913.6 426.2 426.3 521.3 521.4 506.3 506.5 45 
L Pneu 939.5 939.9 426.2 426.5 547.3 547.6 532.3 532.9 3 
V Pneu 925.5 925.9 426.2 426.6 533.3 533.8 518.3 518.7 14 
Nle Pneu 939.5 939.8 426.2 426.5 547.3 547.6 532.3 532.9 22 
F Pneu 973.5 973.9 426.2 426.5 581.3 581.8 566.3 566.7 38 
C Pneu 929.4   n.d. 426.2   n.d. 537.2  n.d.  522.2  n.d.    n.d. 
A Mono 897.4 897.6 426.2 426.5 505.3 505.7 490.3 490.6 16 
L Mono 939.5 939.8 426.2 426.6 547.3 547.8 532.3 532.9 0 
V Mono 925.5 926.0 426.2 426.5 533.3 533.8 518.3 518.7 9 
Nle Mono 939.5 939.8 426.2 426.5 547.3 547.6 532.3 532.9 54 
F Mono 973.5 973.9 426.2 426.4 581.3 581.8 566.3 566.6 20 
C Mono 929.4   n.d. 426.2  n.d.  537.2  n.d.  522.2   n.d.  n.d.  
L Fae 939.5 939.8 426.2 426.5 547.3 547.6 532.3 532.8 9 
C Fae 929.4   n.d. 426.2   n.d. 537.2  n.d.  522.2  n.d.    n.d. 
A Lactis 897.4 897.6 426.2 426.4 505.3 505.7 490.3 490.6 17 
L Lactis 939.5 939.8 426.2 426.4 547.3 547.6 532.3 532.9 3 
V Lactis 925.5 926.0 426.2 426.5 533.3 533.8 518.3 518.7 16 
F Lactis 973.5 973.9 426.2 426.4 581.3 581.8 566.3 566.7 44 
C Lactis 929.4  n.d.  426.2  n.d.  537.2  n.d.  522.2   n.d.  n.d.  
A Strep 897.4 897.7 426.2 426.5 505.3 505.7 490.3 490.6 17 
L Strep 939.5 939.8 426.2 426.4 547.3 547.6 532.3 532.8 3 
F Strep 973.5 973.9 426.2 426.4 581.3 581.8 566.3 566.7 20 
V Strep 925.5 925.8  426.2  426.3 533.3  533.7 518.3 518.6   2 
C Strep 929.4   n.d. 426.2   n.d. 537.2   n.d. 522.2   n.d. n.d.  
L Anth 939.5 939.8 426.2 426.6 547.3 547.6 532.3 532.9 3 
C Anth 929.4  n.d.  426.2  n.d.  537.2   n.d. 522.2  n.d.   n.d.  
L Plant 939.5 939.8 426.2 426.5 547.3 547.6 532.3 532.9 25 
C Plant 929.4   n.d. 426.2   n.d. 537.2   n.d. 522.2   n.d.  n.d. 
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Abz-LPATXG-K(DNP) Discrete Hits LC-ESI-MS Analysis 
 
Substrate Fragment 
Transpeptidation 
Product 
Hydrolysis 
Product / 
Hydrolysis 
Ratio 
X = Sortase Calcd Obs Calcd Obs Calcd Obs Calcd Obs 
 
A Suis 941.4 941.7 440.2 440.2 535.3 535.5 520.3 520.3 27 
S Suis 957.4 957.9  456.2  456.5 535.3  535.7 520.3  520.3  133 
N Suis 984.5 984.9 483.2 483.6 535.3 535.6 520.3 520.3 85 
C Suis 973.4  n.d. 472.2   n.d. 535.3  n.d.  520.3   n.d.  n.d.  
A Oralis 941.4 941.7 440.2 440.2 535.3 535.4 520.3 520.5 17 
S Oralis 957.4   n.d. 456.2  n.d.  535.3  n.d.  520.3  n.d.   n.d.  
C Oralis 973.4  n.d  472.2 n.d   535.3  n.d  520.3  n.d  n.d   
A Pneu 941.4 941.7 440.2 440.3 535.3 535.5 520.3 520.4 13 
S Pneu 957.4 957.7 456.2 456.4 535.3 535.6 520.3 520.6 10 
V Pneu 969.5 969.8 468.2 468.6 535.3 535.6 520.3 520.4 59 
Nle Pneu 983.5 984.0 482.2 482.4 535.3 535.6 520.3 520.5 121 
L Pneu 983.5 984.1 482.2 482.3 535.3 535.7 520.3 520.6 102 
N Pneu 984.5  984.9 483.2  483.6 535.3  535.6 520.3  520.5  90 
F Pneu 1017.5 1017.8 516.2 516.3 535.3 535.5 520.3 520.5 146 
C Pneu 973.4  n.d  472.2 n.d   535.3 n.d   520.3  n.d   n.d  
S Mono 957.4  957.7 456.2  456.5 535.3  535.6 520.3 520.6  12  
Y Mono 1033.5 1033.9 532.2 532.7 535.3 535.6 520.3 520.5 1 
N Mono 984.5 985.0 483.2 483.6 535.3 535.6 520.3 520.6 63 
F Mono 1017.5 1017.8 516.2 516.3 535.3 535.6 520.3 520.4 14 
C Mono 973.4  n.d. 472.2  n.d. 535.3  n.d. 520.3 n.d.   n.d. 
A Lactis 941.4 941.5 440.2 440.4 535.3 535.5 520.3 520.5 235 
S Lactis 957.4 957.7 456.2 456.5 535.3 535.6 520.3 520.7 386 
N Lactis 984.5  984.8 483.2  483.5 535.3 535.5  520.3  520.5 109  
C Lactis 973.4  n.d  472.2  n.d  535.3 n.d   520.3  n.d   n.d  
A Strep 941.4 941.6 440.2 440.2 535.3 535.5 520.3 520.2 21 
S Strep 957.4 957.8 456.2 456.5 535.3 535.6 520.3 520.6 2 
Y Strep 1033.5 1033.7  532.2  532.7 535.3 535.5  520.3  520..5  4 
C Strep 973.4 n.d  472.2 n.d   535.3  n.d  520.3 n.d   n.d   
A Anth 941.4 941.6 440.2 440.3 535.3 535.4 520.3 520.3 0 
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3. Progress Toward Chemoenzymatic Synthesis of Plant Cyclotides  
3.1 Plant Cyclotides and Sortase-Mediated Cyclizations 
 As a demonstration of the utility of sortase A homologs with altered substrate 
selectivity, we explored the synthesis of the naturally occurring cyclic plant protein 
Kalata B1.87 This small protein is a member of a large class of naturally cyclic 
polypeptides termed cyclotides.88-90 Structurally, these molecules are unique as they 
have a fused, cyclic polypeptide backbone with additional crosslinks provided by 
intramolecular disulfide bonds (Figure 25).91  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Structure of Kalata B1 and its six cysteine residues and three disulfide bonds (In yellow) 
 
These structural features endow cyclotides with remarkable stability toward 
thermal, chemical, or enzymatic degradation.88,92 These proteins have also 
generated significant interest as therapeutics as many have shown antibacterial, 
insecticidal93, and anti-HIV activity94. In addition, the defined structure of cyclotides 
are recognized as useful scaffolds for protein engineering applications aimed at 
developing novel protein therapeutics.95,96 Given this potential, methods for the 
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synthesis of native and modified cyclotides are highly desirable. At present, most 
approaches have relied on laborious solid-phase synthesis followed by macrocyclic 
ring closure, often employing native-chemical ligation (NCL).90,97,98 While effective, 
the installation of the requisite C-terminal thioester for NCL is challenging in the 
context of solid-phase synthesis, and depending on the particular method of solid-
phase synthesis employed, the need for highly toxic hydrofluoric acid (HF) may be 
required. In total, while methods for generating cyclotides have been reported, there 
remain considerable opportunities to develop alternate approaches that improve 
efficiency and ease of synthesis. 
 Bacterial sortases provide a compelling alternative for generating cyclic 
polypepetides. Linear precursors containing a N-terminal glycine and a C-terminal 
LPXTG motif have been shown to undergo highly efficiency N- to C-terminal ligation 
in the presence of SrtAStaph (Figure 26a).89 This approach has been applied to a 
number of polypeptide targets, including GFP89, Cre recombinase89, GCSF99, 
IFNα99, lactoferricin100, and even some plant cyclotides101. However, in the case of 
plant cyclotides, presumably constrained by the LPXTG specificity of SrtAStaph, the 
authors were required to insert additional residues to generate SrtAStaph-compatible 
ligation sites.89,101 In the case of Kalata B1, four additional amino acids were 
installed in the linear precursor (Figure 26b). This resulted in a LPVTGGGC ligation 
site, rather than the native LPVCG sequence.101 While this permitted cyclization to 
occur, the resulting derivative showed a decrease in serum stability relative to native 
Kalata B1, and the normally facile formation of intrachain disulfides in native Kalata 
B1 was disrupted.  
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Figure 26. a) Natural protein circulization using SrtA staph. b) Circulization of non-natural Kalata B1 
using SrtAStaph. c) Circulization of wild type Kalata B1 using various sortases.  
 
Upon careful inspection of the linear sequence of Kalata B1 and numerous other 
cyclotides, we noted that many contained stretches of amino acids that were similar, 
though not exact matches of the standard SrtAStaph LPXTG motif. In the case of 
Kalata B1, a LPVCGE motif was identified.87 Given our substrate profiling data 
described in Chapter 2 of this thesis, we hypothesized that one or more of our 
sortase homologs would be able to process this substrate, and therefore provide a 
direct route to synthesizing this cyclotide without the need for other non-natural 
amino acid insertions (Figure 26c). 
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3.2 Model Peptide Studies for Kalata B1 Ring Closure 
 To begin testing our synthetic route, we first synthesized a model peptide 
containing the potential ligation site present in Kalata B1. This material was 
generated using the solid-phase peptide synthesis methods described above, and 
purified to homogeneity by RP-HPLC (Figure 27a). With this peptide in hand, we 
then evaluated the ability of each of our sortase homologs to catalyze a model 
transpeptidation reaction using a small diglycine peptide as the amine nucleophile 
(Figure 27b). As anticipated, we observed that more than one sortase homolog was 
able to process this sequence, with reaction conversions in multiple cases reaching  
>70% (Figure 27c). Moreover, it was observed that sortase homologs other than 
SrtAStaph provided the highest reaction conversions, underscoring the value of 
utilizing these alternate enzymes.  
 In addition to reaction conversion data, we also analyzed reactions by LC-
ESI-MS. In the case of reactions reaching 25% conversion or better, the presence of 
the expected transpeptidation product was clearly identified at m/z = 664.7 Da 
(calculated mass = 664.3 Da). A hydrolysis by-product was also detected, though in 
most cases transpeptidation was formed as the major product (Figure 27d). 
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Figure 27. a) Characterization of model transpeptidation reaction representing a potential ligation site 
for Kalata B1 synthesis. b) Overview of model transpeptidation reaction. Conditions: 25 μM sortase 
homolog, 200 μM peptide, and 1 mM GG in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+ 
incubated at room temperature for 24 hours followed by analysis by RP-HPLC. c) Transpeptidation 
activity of sortase A homologs estimated by RP-HPLC. Values represent % reaction 
conversion. d) LC-ESI-MS characterization of transpeptidation reaction products.  
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3.3 Design and Expression of Linear Kalata B1 Fusion Protein 
  Having observed successful transpeptidation in our peptide model system, we 
turned our attention to generating a linear precursor for full length Kalata B1. With 
the goal of avoiding the need for solid phase synthesis, we envisioned a 
recombinant protein construct in which the linear Kalata B1 precursor was fused at 
the C-terminus of maltose binding protein (MBP) via a standard sortase LPXTG site 
(Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Proposed synthetic scheme for preparation of wild type Kalata B1 
MBP -GGGGSLPATGETCVGGTCNTPGCTCSWPVCTRNGLPVCGEG 
Linear Kalata B1 
sortase 
cleavage 
sortase 
cleavage 
sortase homolog 
(cleavage 1) 
GETCVGGTCNTPGCTCSWPVCTRNGLPVCGEG 
sortase homolog 
(cyclization) 
GETCVGGTCNTPGCTCSWPVCTRNGLPVC 
cyclic Kalata B1 intermediate 
disulfide formation 
wild type Kalata B1 
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Overall, this construct would then possess two sortase substrate motifs. Initial 
cleavage would generate a linear Kalata B1 precursor containing a N-terminal 
glycine and a C-terminal LPVCG site. Subsequent transpeptidation would then yield 
the cyclic backbone of Kalata B1. The final step in this process would require 
oxidation to generate the intramolecular disulfide bonds, a process that has been 
shown to proceed spontaneously upon formation of the cyclic backbone. 
The expression vector for MBP-Kalata-B1 containing a N-terminal His6 tag 
was obtained via commercial gene synthesis from DNA 2.0 (Menlo Park, CA). 
Expression of this protein in E. coli BL21(DE3) cells was achieved using standard 
molecular biology techniques. MBP-Kalata-B1 was purified using Ni-NTA 
chromatography (Figure 29). Characterization by SDS-PAGE revealed a strong 
band with an appropriate molecular weight and minimal impurities.  
 
 
 
 
 
 
 
 
Figure 29. SDS-PAGE analysis of MBP-Kalata B1 expressed and purified from E. coli. W1, W2, and 
W3 represent Ni-NTA column wash fractions, and E1 and E2 represent the eluted fractions containing 
purified MBP-Kalata-B1. 
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3.4 One-Pot Kalata B1 Cyclization using Sortase Homologs 
 With MBP-Kalata-B1 in hand, we next explored the ability of different sortase 
homologs to catalyze the one-pot cleavage and cyclization scheme illustrated in 
Figure 30a. For these reactions, 50 μM MBP-Kalata-B1 was combined with 25 μM 
sortase homolog, 100 mM DTT, and 10 mM H2NOH. DTT was included to keep all 
cysteine residues in Kalata B1 in reduced form, and H2NOH was added to assist 
with the cleavage of the standard sortase substrate motif (LPETG) linking Kalata B1 
to the MBP carrier protein. Reactions were incubated overnight at 37 degrees 
Celsius. 
When analyzed by SDS-PAGE, numerous homologs exhibited the ability to 
cleave the full-length MBP-Kalata-B1 precursor, giving rise to a new band at slightly 
lower apparent molecular weight (Figure 30a). Based on the relative intensity of gel 
bands, SrtAStaph and SrtAStrep were most reactive in this transformation. In order to 
probe for the presence of the cyclic Kalata B1 product, these reactions were further 
subjected to LC-ESI-MS analysis. We were delighted to observe the presence of a 
distinct peak in the mass spectra that corresponded to the M+3H+ ion of the desired 
cyclic Kalata B1 intermediate. As shown in Figure 30b, SrtAStrep and SrtAStaph 
generated peaks at m/z = 966.9 and m/z = 966.5, respectively, that closely matched 
the calculated m/z of 966.4. Importantly, these signals were absent from a control 
reaction consisting of full length MBP-Kalata-B1 that was incubated with DTT and 
H2NOH in the absence of any sortase homolog. In addition, mass spectrometry 
revealed that the reaction catalyzed by SrtAStaph contained significant contamination 
by the non-cyclized Kalata B1 fragment following initial cleavage from the MBP 
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carrier protein. In contrast, the SrtAStrep catalyzed reaction showed very little of this 
intermediate, indicating that this enzyme was more efficient at promoting the final 
macrocyclic ring closure. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 30. a) Reaction scheme of Kalata B1 synthesis. SDS-PAGE gel of the reaction of MBP-
Kalata-B1 with various sortase homologs. Reaction conditions: 25 μM sortase homolog, 50 μM MBP-
Kalata-B1, and 10 mM hydroxylamine in aqueous Tris buffer (pH 7.5) containing 10 mM Ca2+ 
incubated at 37 oC for 24 hours. b) Analysis of select reactions by LC-ESI-MS. Expected mass for the 
M+3H+ ion of cyclic Kalata B1 intermediate = 966.4. 
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While preliminary, these studies provide compelling evidence that the 
promiscuous substrate selectivity of alternate sortase homologs can be leveraged 
for the efficient synthesis of plant cyclotides. Going forward, our goal is to isolate the 
putative cyclic Kalata B1 intermediate, and verify its identity by comparison to 
authentic Kalata B1 using RP-HPLC and mass spectrometry. A critical component of 
this effort will include determining the oxidation state of the cysteine residues in our 
Kalata B1 product. As described above, the spontaneous formation of the desired 
disulfide bond arrangement has been shown to proceed readily once the polypeptide 
backbone has been cyclized. Once the identity of our Kalata B1 product has been 
confirmed, we will then optimize this process with respect to reaction temperature, 
buffer identity, and reagent loading to maximize the formation of Kalata B1. In the 
long term, we envision that this strategy will be amenable to the construction of other 
plant cyclotides containing amino acid sequences within the substrate scope of our 
sortase homologs.   
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4. Conclusions & Future Directions  
In this work we have elucidated the substrate preferences of ten naturally 
occurring sortase A homologs. Initially all ten homologs were believed to be LPXTG-
specific based on bioinformatics studies. Yet, through extensive screening using our 
strategies we were able to conclude that the in vitro substrate flexibility far exceeds 
bioinformatics predictions. Prior to our study, 19 substrate sequences were known 
that were compatible with sortase-mediated protein modification.64,67-69,71,74,75 
Through our work, we were able to enhance reaction conversion involving 4 of the 
previously known sequences, and in addition we identified 15 brand new substrate 
sequences. In total, this work has provided new tools for chemoenzymatic protein 
modification, and has expanded the substrate scope for sortase-based methods.  
In addition to the immediate conclusions of this work, our studies also suggest 
areas for further exploration and development. For example, our data suggest that 
certain substrate sequences are specific to individual sortase A homologs. As a 
result we envision that certain enzymes and substrate pairs can operate 
independently and serve as orthogonal ligation systems. Using these, one potentially 
can perform complex labeling schemes such as multiple modifications in one 
protein, or simultaneous labeling of multiple proteins in complex mixtures.   
Another exciting application that directly uses the sortases described here is 
the synthesis of isopeptide bonds. Currently, sortase-mediated ligation is limited to 
the C- and N-termini. Two of the sortase A homologs (SrtASuis and SrtAOralis) are 
predicted to utilize the ε-amine side chain of lysines, which naturally results in 
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isopeptide bond ligation in vivo.37,63 Having elucidated the substrate preferences of 
these enzymes in this study gives potential insight for exploring isopeptide bond 
ligation using these two sortase A homologs. This may result in a new approach to 
site-specifically installing various labels at internal sites within protein targets.  
Another direction, which builds upon our work with Kalata B1, is to expand the 
cyclic protein synthesis to other known cyclotides. Numerous cyclotides contain 
sequences that are highly similar to the standard LPXTG substrate. These include, 
LPXCG, IPXCG, LXATGM, and others.87 Currently, we have work in progress on 
synthesizing Cycloviolacin T1, which contains an IPXCG sequence. This ultimately 
allows further expansion of cyclic protein synthesis using sortases and exploits the 
variations in substrate selectivity exhibited by sortase A homologs studied in this 
work.  
Finally, studies here give a foundation for understanding the biochemical 
mechanisms of sortase activity. Structural studies will allow us to understand further 
the behavior of these sortases with respect to substrate recognition. This would 
contribute to fundamentally understanding of sortase enzymology and assist in the 
use of sortases for protein engineering. In addition, sortases are recognized as 
targets for therapeutic intervention in the treatment of bacterial infections, and 
therefore structural studies can provide information for developing inhibitors of this 
enzyme.44,102  
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5. Experimental 
5.1 Protein Expression and Purification 
Sequences of proteins used in this study: 
SrtAStaph (initiator methionine absent in purified protein) 
GSSHHHHHHSSGLVPRGSHMQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPE
QLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETR
KYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK 
 
SrtAAnth (initiator methionine absent in purified protein) 
GSSHHHHHHSSGLVPRGSHMDASKIDQPDLAEVANASLDKKQVIGRISIPSVSLEL
PVLKSSTEKNLLSGAATVKENQVMGKGNYALAGHNMSKKGVLFSDIASLKKGDKIY
LYDNENEYEYAVTGVSEVTPDKWEVVEDHGKDEITLITCVSVKDNSKRYVVAGDLV
GTKAKK 
 
SrtAPneu 
MESSHHHHHHAVLTSQWDAQKLPVIGGIAIPELEMNLPIFKGLDNVNLFYGAGTMK 
REQVMGEGNYSLASHHIFGVDNANKMLFSPLDNAKNGMKIYLTDKNKVYTYEIREV
KRVTPDRVDEVDDRDGVNEITLVTCEDLAATERIIVKGDLKETKDYSQTSDEILTAFN
QPYKQFY 
 
SrtALac 
MESSHHHHHHAAVKSVDFQSVLTNQFNSQPLPVIGGIAIPELNINLPIFKGVGNTS 
LLYGAGTMKADEVMGEGNYSLAGHNMTGFTSDLSILFTPLEKAKAGMTIYVTDKDN
IYQYKIDKIDVVTPEHVEVINDSPGKKEITLVTCADAEATHRIIVHGTFVDKTSYDKAT
DTMKNAFETKYNQIKNF 
 
SrtAFae 
MESSHHHHHHVESLSTEAVMKAQFENKNLPVIGAIAIPSVEINLPIFKGLSNVALL 
TGAGTMKEDQVMGKNNYALASHRTEDGVSLFSPLERTKKDELIYITDLSTVYTYKIT
SVEKIEPTRVELIDDVPGQNMITLITCGDLQATTRIAVQGTLAATTPIKDANDDMLKA
FQLEQKTLADWVA 
 
SrtAMono 
MESSHHHHHHGAANYDKDAVVGSIAVPSVDVNLLVFKGTNTANLLAGATTMRSDQ
VMGKGNYPLAGHHMRDESMLFGPIMKVKKGDKIYLTDLENLYEYTVTETKTIDETE
VSVIDDTKDARITLITCDKPTETTKRFVAVGELEKTEKLTKELENKYFPSK 
 
SrtASuis 
MESSHHHHHHSSGLVPRGSAILAAQWDAQRLPVIGGIAVPELGINLPIFKGVFNTSL
MYGAGTMKENQEMGKGNYALASHHIFGVTGAADVLFSPLDRAKNGMKIYITDKTN
VYTYVIDSVEIVSPESVYVIDDVEGRTEVTLVTCTDYYATQRIVVKGVLESTTPYNET
AKDILDSFNKSYNQYDYG 
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SrtAOralis 
MESSHHHHHHSSGLVPRGSAVLASQWDAQKLPVIGGIAIPEVEINLPIFKGLDNVNL
FYGAGTMKPDQKMGEGNYSLASHHIFTAENASQMLFSPLVNAKAGMKIYLTDKDK
VYTYEITEVKRVTPDRVDEIEDRDGVKEITLVTCVDYNATERIIVKGIFKESKAYSETS
EDILKAFNQPYRQRY 
 
SrtAPlant (maltose binding protein fusion) 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGD
GPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEA
LSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAF
KYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTI
NGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLEN
YLLTDEGLEAVNKDKPLGAVALKSYEEELVKDPRIAATMENAQKGEIMPNIPQMSAF
WYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRISHMSMES
SHHHHHHKSLDFQTVAKARMNKNAINVIGSIAIPSVDLYLPIGNGVSNETLALAAGT
MKANQKMGQGNYALAGHHMIKHGALFSPLYYKSKVGQMIYVSDAKKIYAYKTSQR
TFIKATDVQVIDDVPGQKLITLITCDKTGAGRLMIRGKYEQQWSFKSAPTQVQKAFT
SHFNNKY 
 
SrtAStrep (maltose binding protein fusion) 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGD
GPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEA
LSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAF
KYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTI
NGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLEN
YLLTDEGLEAVNKDKPLGAVALKSYEEELVKDPRIAATMENAQKGEIMPNIPQMSAF
WYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRISHMSMDS
SHHHHHHSSGLVPRGSVLQAQMAAQQLPVIGGIAIPELGINLPIFKGLGNTELIYGA
GTMKEEQVMGGENNYSLASHHIFGITGSSQMLFSPLERAQNGMSIYLTDKEKIYEYI
IKDVFTVAPERVDVIDDTAGLKEVTLVTCTDIEATERIIVKGELKTEYDFDKAPADVLK
AFNHSYNQVST 
 
MBP-Kalata-B1 
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQ
VAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIA
YPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAA
DGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNK
GETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKEL
AKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMP
NIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNLEVLFNSSSNNNNNNNNNN
LGIEGRISHMLEVLFQGPMGGGGSLPATGETCVGGTCNTPGCTCSWPVCTRNGL
PVCGEG 
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Plasmids. The pET-28a+ expression vector for SrtAStaph was provided by Prof. Hidde 
Ploegh (Whitehead Institute for Biomedical Research). The pET-15b expression 
vector for SrtAAnth was provided by Professor Robert Clubb (UCLA). Vectors for 
SrtALac, SrtAPneu, SrtAFae, SrtAMono, and MBP-Kalata-B1 were obtained via 
commercial gene synthesis (pJ414 expression vector) from DNA2.0 (Menlo Park, 
CA).  
The catalytic domain of SrtAPlant was originally acquired through commercial 
gene synthesis (pJ414 vector) from DNA 2.0. To improve solubility, the SrtAPlant 
coding region was subcloned into the pMAL-C5x plasmid (New England Biolabs) to 
generate a maltose binding protein (MBP) fusion. Briefly, the SrtAPlant gene was 
excised from the parent pJ414 vector by double digestion with EcoRI (Fisher 
OptizymeTM) and NcoI (Fisher OptizymeTM) following the manufacturer’s instructions. 
The insert was then purified by agarose gel electrophoresis and isolated using a 
GeneJET Gel Extraction Kit (Thermo Scientific). pMAL-C5x was linearized and 
purified in a similar fashion. The SrtAPlant insert was then ligated using T4 DNA ligase 
(Fisher OptizymeTM) following the manufacter’s instructions, and successful clones 
were confirmed by sequencing.  
A pET-28a+ expression vector containing the catalytic domain of SrtAStrep was 
provided by Prof. Hidde Ploegh (Whitehead Institute for Biomedical Research). Due 
to difficulties encountered during purification, the SrtAStrep coding region was 
subcloned into the pMAL-C5x plasmid (New England Biolabs) to generate a maltose 
binding protein (MBP) fusion. First, the SrtAStrep gene was PCR amplified using the 
following primers to install NcoI and EcoRI restriction sites:  
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Forward 5′-TATACCATGGACAGCAGCCATCATCATC-3′  
 
Reverse 5′-GTCCGCTGAATTCTTAGGTAGATACTTGGTTATAAG-3′ 
 
 A Phusion High-Fidelity PCR Kit (Thermo Scientific) was used for PCR following the 
manufacturer’s instructions. The PCR amplified product was then purified by 
agarose gel electrophoresis and isolated using a GeneJET Gel Extraction Kit 
(Thermo Scientific). The SrtAStrep insert was then cloned into pMAL-C5x via the NcoI 
and EcoRI restriction sites, and successful clones were confirmed by sequencing.  
 The catalytic domain of SrtASuis fused to a N-terminal His6-tag and flanked by 
NcoI and EcoRI restriction sites was purchased as a GeneArt® StringTM (Invitrogen). 
This construct was digested using EcoRI and NcoI following the manufacturer’s 
instructions. The insert was then purified by agarose gel electrophoresis and isolated 
using a GeneJET Gel Extraction Kit (Thermo Scientific). The SrtASuis insert was then 
cloned into the pJ414 backbone (DNA 2.0) via the NcoI and EcoRI restriction sites, 
and successful clones were confirmed by sequencing. 
 The catalytic domain of SrtAOralis fused to a N-terminal His6-tag and flanked by 
NcoI and EcoRI restriction sites was purchased as a GeneArt® StringTM (Invitrogen). 
This construct was PCR amplified using the following primers: 
Forward 5′-ATCGATCCATGGAAAGCA-3′  
Reverse 5′-ATCGATGAATTCTTAATAACGCT-3′ 
A Phusion High-Fidelity PCR Kit (Thermo Scientific) was used for PCR following the 
manufacturer’s instructions. The PCR amplified product was then purified by 
agarose gel electrophoresis and isolated using a GeneJET Gel Extraction Kit 
(Thermo Scientific). The SrtAoralis insert was then cloned into pJ414 (DNA2.0) via the 
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NcoI and EcoRI restriction sites, and successful clones were confirmed by 
sequencing. 
 
General Protocol for Protein Expression. Expression vectors for sortase homologs 
and MBP-cyclotide fusions were transformed (heat shock) into Escherichia coli 
BL21(DE3) cells and plated on agar plates supplemented with appropriate antibiotics 
(100 µg/ml ampicillin or 50 µg/ml kanamycin). After overnight incubation at 37 oC, 
single colonies were selected and used to inoculate 100 mL starter cultures 
containing sterile LB media and appropriate antibiotics. A portion of the starter 
culture (~25 mL) was used to inoculate 1 L of sterile LB containing antibiotics (100 
µg/ml ampicillin or 50 µg/ml kanamycin), and the cells were grown at 37 oC to an 
optical density of ~0.8 at 600 nm. Protein expression was induced with IPTG (1 mM 
final concentration) for 3 hours at 37 oC. The cells were then harvested by 
centrifugation, followed by resuspension of the bacterial pellets in ~40 mL of buffer 
(20 mM Tris pH 8.0, 150 mM NaCl, and 0.5 mM EDTA). Lysozyme was then added 
to a final concentration of 1 mg/ml, and the mixture was incubated for 2 h at 4 oC on 
a rocking platform. The suspension was then sonicated and centrifuged. The 
clarified lysate was then applied to a nickel nitrilotriacetic acid (Ni-NTA) column 
containing 5 mL of Ni-NTA agarose slurry (Thermo Scientific) that had been pre-
equilibrated with ~10 mL of 20 mM Tris pH 8.0, 150 mM NaCl, and 20 mM imidazole. 
After binding proteins to the column, it was washed with 30 mL of 20 mM Tris pH 
8.0, 150 mM NaCl, and 20 mM imidazole. Proteins were then eluted with three 5 mL 
portions of 20 mM Tris pH 8.0, 150 mM NaCl, and 300 mM imidazole. Purified 
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proteins were dialyzed against either 20 mM Tris pH 7.5, 150 mM NaCl (MBP-
cycloide fusions) or 20 mM Tris pH 8.0, 150 mM NaCl (all sortase homologs) at 4 oC 
to remove imidazole. Glycerol was then added to the dialyzed solutions (final 
glycerol concentration 10% (v/v)), and aliquots were stored at -80 oC. All protein 
concentrations were estimated by absorbance at 280 nm using calculated extinction 
coefficients (Expasy ProtParam tool). The purity of each protein was evaluated by 
SDS-PAGE analysis. 
 
 
5.2 Peptide Synthesis and Purification 
Materials and Instrumentation. Unless otherwise noted, all chemicals were obtained 
from commercial sources and used without further purification. Fmoc Rink Amide 
MBHA resin and a colorimetric ninhydrin test kit were purchased from Anaspec. 
Fmoc-L-Ala-OH, Fmoc-L-Gly-OH, Fmoc-L-Ser(OtBu)-OH, Fmoc-L-Thr(OtBu)-OH, 
Fmoc-L-Val-OH, Fmoc-L-Leu-OH, Fmoc-L-Ile-OH, Fmoc-L-Nle-OH, Fmoc-L-Pro-
OH, Fmoc-L-Phe-OH, Fmoc-L-Tyr(OtBu)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-
Glu(OtBu)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Asn(Trt)-OH, 
Fmoc-L-His(Trt)-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Cys(Trt)-
OH, Boc-2-aminobenzoic acid and O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) were purchased from Chem-
Impex International. Piperidine was obtained from Alfa Aesar. N,N′-
diisopropylethylamine (DIPEA), peptide synthesis grade trifluoroacetic acid (TFA), 
dimethyl sulfoxide (DMSO), hydroxylamine hydrochloride, and methylene chloride 
(CH2Cl2) were obtained from Fisher Scientific. N-methyl-2-pyrrolidone (NMP) was 
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purchased from either Fisher Scientific or Advanced Chemtech. Fmoc-L-Lys(DNP)-
OH was obtained from Anaspec of Chem-Impex International. Dithiothreitol (DTT) 
was purchased from Gold Biotechnology. Triisopropylsilane (TIPS) were obtained 
from Acros. Diethyl ether was purchased from J.T. Baker. ChromAR® grade 
acetonitrile (MeCN) was obtained from Macron Fine Chemicals. Water used in 
biological procedures or as a reaction solvent was purified using a Milli-Q Advantage 
A10 system (Millipore). 
HPLC purifications and analyses were achieved using a Dionex Ultimate 
3000 HPLC system. Analytical scale separations were performed with a 
Phenomenex Kinetex 2.6 μm, 100 Å C18 column (3.0 x 100 mm). Analytical scale 
analyses were achieved using the following method (Method A): MeCN (0.1% TFA) / 
H2O (0.1% TFA) mobile phase. Flow rate = 0.7 mL/min. Gradient = 10% MeCN (0.0-
0.5 min), 10% MeCN  90% MeCN (0.5-6.0 min), hold 90% MeCN (6.0-7.0 min), 
90% MeCN  10% MeCN (7.0-7.1 min), re-equilibrate at 10% MeCN (7.1-10.0 min). 
Semi-preparative purifications were performed with a Phenomenex Luna 5 μm, 100 
Å C18 column (10 x 250 mm). Semi-preparative purifications were achieved using 
the following method (Method B): MeCN (0.1% TFA) / H2O (0.1% TFA) mobile 
phase. Flow rate = 0.5  4.0 mL/min (0.0-2.0 min), hold 4.0 mL/min (2.0-17.01 min), 
4.0  0.5 mL/min (17.01-19.0 min). Gradient = 20% MeCN (0.0-2.0 min), 20% 
MeCN  90% MeCN (2.0-15.0 min), hold 90% MeCN (15.0-17.0 min), 90% MeCN 
 10% MeCN (17.0-17.01 min), re-equilibrate at 10% MeCN (17.01-19.0 min).  
Liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-
MS) analysis was carried out with an API 2000 Triple Quadrupole mass 
 73 
 
spectrometer (Applied Biosystems) and an Agilent 1100 HPLC system equipped 
with a Phenomenex Aeris Widepore 3.6 μm 200 Å XB-C8 column (4.6 x 150 mm). 
All samples were analyzed using the following method: H2O (0.1% formic acid) / 
organic (95% MeCN, 5% isopropanol, 0.1% formic acid) mobile phase. Flow rate = 
1.25 mL/min. Gradient = 10% organic (0.0-1.0 min), 10% organic  90% organic 
(1.0-10.0 min). Deconvolution of protein charge ladders was achieved using a 
maximum entropy algorithm provided by Analyst 1.4.2 software. 
UV-vis spectroscopy was performed on a NanodropTM ND-1000 
spectrophotometer (Thermo Scientific, USA). 
 
General Peptide Synthesis Methods. All peptides were synthesized using manual 
Fmoc solid phase peptide synthesis (SPPS). Syntheses were performed in Extract 
CleanTM SPE 15 mL reservoirs fitted with appropriate frits and inlet/outlet caps. All 
manipulations (washing, coupling, deprotection, etc.) were conducted at room 
temperature and included gentle agitation on a bench-top rocking platform unless 
otherwise indicated. 
 
Synthesis of Peptide Libraries using Isokinetic Couplings. Solid phase synthesis 
reservoirs were loaded with Fmoc-protected Rink amide MBHA resin (0.2 mmol 
scale). Resins were initially washed/swollen with ~10 mL of NMP (3x, 10 min per 
wash). Fmoc removal was achieved by treatment with 10 mL of 80:20 
NMP/piperidine at room temperature (2x, 10 min per treatment). Resins were then 
washed with ~10 mL of NMP (3x, 5-10 min per wash). Peptide libraries were then 
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assembled using a combination of standard, single amino acid couplings and 
isokinetic couplings of amino mixtures. For single residue coupling the following 
procedure was employed: Fmoc-protected amino acid (0.60 mmol, 3.0 equivalents 
relative to resin loading), HBTU (0.60 mmol), and DIPEA (1.0 mmol) were dissolved 
in 3.0 mL of NMP. This solution was mixed thoroughly, and then added to the 
deprotected resin. Couplings were incubated for ~1 h at room temperature. Resins 
were then washed with ~10 mL of NMP (3x, 5-10 min per wash). The success of 
each coupling reaction was assessed using a colorimetric ninhydrin test. In the event 
that the coupling was incomplete, the amino acid coupling step was repeated. Fmoc 
deprotection was then carried out by washing with 10 mL of 80:20 NMP/piperidine 
(2x, 10 min per treatment), followed by washing with ~10 mL of NMP (3x, 5-10 min 
per wash). Repeated cycles of amino acid coupling and Fmoc deprotection were 
then performed to assemble the desired peptide sequences. Randomization of 
select positions using isokinetic amino acid coupling was achieved using a variation 
of the above coupling procedure. First, HBTU (2.0 mmol) and DIPEA (4.0 mmol) 
were dissolved in 10 mL of NMP along with the mixture of Fmoc-protected acids 
listed in the following Table 6. 
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Table 6. Composition of isokinetic mixture using in library synthesis.77 
Amino Acid Building Block Mass (mg) mmol 
Fmoc-Gly-OH 17 0.058 
Fmoc-L-Ala-OH 21 0.068 
Fmoc-L-Thr(OtBu)-OH 38 0.096 
Fmoc-L-Ser(OtBu)-OH 21 0.056 
Fmoc-L-Val-OH 77 0.226 
Fmoc-L-Leu-OH 35 0.098 
Fmoc-L-Ile-OH 123 0.348 
Fmoc-L-Nle-OH 27 0.076 
Fmoc-L-Tyr(OtBu)-OH 38 0.082 
Fmoc-L-Trp(Boc)-OH 40 0.076 
Fmoc-L-Asp(OtBu)-OH 29 0.070 
Fmoc-L-Glu(OtBu)-OH 31 0.072 
Fmoc-L-Asn(Trt)-OH 63 0.106 
Fmoc-L-Gln(Trt)-OH 65 0.106 
Fmoc-L-Pro-OH 29 0.086 
Fmoc-L-Lys(Boc)-OH 71 0.124 
Fmoc-L-Arg(Pbf)-OH 84 0.130 
Fmoc-L-His(Trt)-OH 43 0.070 
 
The coupling mixture was mixed until homogeneous, and then added to the 
deprotected resin. Isokinetic couplings were incubated for ~12 h at room 
temperature. Resin washing and Fmoc deprotection were then performed as 
described above. Additional Synthesis Notes: A commercially available lysine 
building block (Fmoc-L-Lys(DNP)-OH) was used to install the 2,4-dinitrophenyl 
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(DNP) chromophore. In addition, an aminobenzoic acid (Abz) fluorophore was 
installed at the N-terminus of all peptides through coupling of Boc-2-aminobenzoic 
acid. These building blocks were coupled following the standard single amino acid 
coupling procedure described above. 
 After assembly of the desired peptide sequences, the resins were washed 
with 10 mL of NMP (3x, 10 min per wash), followed by 10 mL of CH2Cl2 (3x, 10 min 
per wash). Libraries were cleaved from the resin by treatment with 5 mL of 
95:2.5:2.5 TFA/TIPS/H2O (2x, ~30 min per treatment). The combined cleavage 
solutions were then concentrated on a rotary evaporator. The remaining residues 
were then precipitated from 40 mL of rapidly stirring, dry-ice chilled diethyl ether. The 
precipitated peptides were then collected by centrifugation, and the crude products 
were dried overnight under vacuum. This material was used without further 
purification. The presence of all predicted peptide sequences was confirmed using 
LC-ESI-MS. Peptide libraries were then dissolved in 1:1 DMSO/H2O, and total 
peptide substrate concentrations were estimated using the absorbance of the DNP 
chromophore at 365 nm (extinction coefficient = 17,400 M-1cm-1). Concentrations 
were then adjusted to yield final stock solutions containing 2 mM total peptide 
substrate.  
 
Synthesis of Discrete Peptide Substrates. Solid phase synthesis reservoirs were 
loaded with Fmoc-protected Rink amide MBHA resin (0.1 mmol scale). Resins were 
initially washed/swollen with ~10 mL of NMP (3x, 10 min per wash). Fmoc removal 
was achieved by treatment with 10 mL of 80:20 NMP/piperidine at room temperature 
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(2x, 20 min per treatment). Resins were then washed with ~10 mL of NMP (3x, 5-10 
min per wash). Suitably-protected amino acids were then coupled as follows: Fmoc-
protected amino acid (0.30 mmol, 3.0 equivalents relative to resin loading), HBTU 
(0.30 mmol), and DIPEA (0.5 mmol) were dissolved in 2.5 mL of NMP. This solution 
was mixed thoroughly, and then added to the deprotected resin. Couplings were 
incubated for ~1 h at room temperature. Resins were then washed with ~10 mL of 
NMP (3x, 5-10 min per wash). The success of each coupling reaction was assessed 
using a colorimetric ninhydrin test. In the event that the coupling was incomplete, the 
amino acid coupling step was repeated. Fmoc deprotection was then carried out by 
washing with 10 mL of 80:20 NMP/piperidine (2x, 10 min per treatment), followed by 
washing with ~10 mL of NMP (3x, 5-10 min per wash). Repeated cycles of amino 
acid coupling and Fmoc deprotection were then performed to assemble the desired 
peptide sequence. Additional Synthesis Notes: A commercially available lysine 
building block (Fmoc-L-Lys(DNP)-OH) was used to install the 2,4-dinitrophenyl 
(DNP) chromophore. In addition, an aminobenzoic acid (Abz) fluorophore was 
installed at the N-terminus of all peptides through coupling of Boc-2-aminobenzoic 
acid. These building blocks were coupled following the standard single amino acid 
coupling procedure described above. 
After assembly of the desired peptides, the resins were washed with ~10 mL 
of NMP (3x, 10 min per wash), followed by ~10 mL of CH2Cl2 (3x, 10 min per wash). 
Peptides lacking cysteine or methionine were cleaved from the resin using a 
cleavage cocktail consisting of 95:2.5:2.5 TFA/TIPS/H2O. For peptides containing 
cysteine, a cleavage cocktail consisting of 88:2:5:5 TFA/TIPS/H2O/DTT (DTT added 
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as a solid to give a final concentration of 5% w/v) was employed. Peptide cleavage 
was achieved by treating resins with 5 mL of the appropriate cleavage cocktail (2x, 
~30 min per treatment). The combined cleavage solutions were then concentrated 
on a rotary evaporator. Crude peptides were then precipitated from 40 mL of rapidly 
stirring, dry-ice chilled diethyl ether. The precipitated peptides were then collected by 
centrifugation, dried overnight under vacuum. All peptides were purified by RP-
HPLC (Method B). Pure fractions were pooled and lyophilized. The identity and 
purity of all peptides was confirmed by RP-HPLC and LC-ESI-MS. Peptides were 
then dissolved in 1:1 DMSO/H2O, and peptide concentrations were estimated using 
the absorbance of the DNP chromophore at 365 nm (extinction coefficient = 17,400 
M-1cm-1). Concentrations were then adjusted to yield 2 mM stock solutions.  
 
5.3 Peptide Library Screening and Peptide Model Reactions 
General Protocol for Sortase-Catalyzed Transacylations using Isokinetic Libraries 
and Discrete Peptide Substrates. Reactions were generally conducted on 50 μL 
scale. The stock solutions shown below (Table 7) were combined in appropriate 
ratios in microcentrifuge tubes, and then diluted with water to give the indicated 
reactant concentrations. All reactions were incubated at room temperature unless 
otherwise indicated. All reactions contained 10% (v/v) 10x SrtA reaction buffer (500 
mM Tris pH 7.5, 1500 mM NaCl, 100 mM CaCl2). Additional notes: the sortase stock 
solutions contained 10% (v/v) glycerol, and therefore all reactions contained small 
amounts of glycerol ≤ 6% (v/v). Additionally, the stock solutions for all peptides were 
prepared in 1:1 DMSO / H2O, and therefore all reactions employing these materials 
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contained DMSO at a final concentration of 5% (v/v). Reactions were analyzed by 
RP-HPLC and LC-ESI-MS. For RP-HPLC, unless otherwise indicated reactions were 
directly injected into the HPLC system and separated using Method A (see above). 
Estimates of reaction progress were obtained by comparing peak areas derived from 
the 365 nm chromatogram. For LC-ESI-MS, reactions were directly injected using 
the method described above. 
 
Table 7. Stock solutions used in sortase-mediated peptide ligation reactions: 
Reagent Concentration Solvent/Buffer 
Abz-LPATXG-K(DNP) 2mM 1:1 DMSO/Water 
Abz-LPAXGG-K(DNP) 2mM 1:1 DMSO/Water 
Abz-LXATGG-K(DNP) 2mM 1:1 DMSO/Water 
Abz-XPATGG-K(DNP) 2mM 1:1 DMSO/Water 
All Discrete Peptides 2 mM 1:1 DMSO/Water 
H2NOHHCl 100mM Water 
GG 10mM Water 
DTT 1 M Water 
β-ME 100 mM Water 
SrtAstaph 444 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAsuis 115 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAoralis 220 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtApneu 89 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAmono 248 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAfaec 354 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAlac 139 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAstrep 44 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAanth 451 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
SrtAplant 281 µM 
90% 50mM Tris pH 8.0, 150 mM NaCl, 10% 
Glycerol (v/v) 
10x SrtA reaction buffer - 
500 mM Tris pH 7.5, 1500 mM NaCl, 100 mM 
CaCl2 
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5.4 Kalata B1 Synthetic Studies 
One-Pot Kalata B1 Cyclization using Sortase Homologs. MBP-Kalata-B1 (14.6 µL of 
a 171 µM stock solution in 20 mM Tris pH 7.5, 150 mM NaCl, 10% (v/v) glycerol) 
was combined with DTT (5.0 µL of a 1 M stock solution in H2O), H2NOHHCl (5.0 µL 
of a 100 mM stock solution in H2O), and 10x sortase reaction buffer (5.0 μL of 500 
mM Tris pH 7.5, 1500 mM NaCl, 100 mM CaCl2). Appropriate amounts of each 
sortase homolog were then added to bring the final enzyme concentration to 25 µM. 
H2O was then added to bring the final volume to 50 μL, and reactions were 
incubated for 24 hours at 37 oC. Reactions were then analyzed by LC-ESI-MS and 
reducing SDS-PAGE and visualized using Coomassie Brilliant Blue R-250 stain. 
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